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Summary 
Cancer metastasis is responsible for 90% of the cancer related deaths; however, 
current drug screening approaches have been ineffective in identifying potent 
therapies that may lead to the cure of the metastatic cancer. Current drug 
screening assays, however, are lacking the ability to mimic physiological cancer 
microenvironments and tumor three-dimensional (3D) structures that may also 
be critically important in the study and prevention of the various processes in 
metastasis. 
Thus, the aim of this study was to develop a microfluidic system that 
integrates a tumor cell model in a 3D hydrogel scaffold, in close co-culture with 
an endothelial monolayer, mimicking part of the in vivo tumor 
microenvironment. In the design of these studies, we recognize that the 
pathophysiology of cancer and mechanisms driving tumor progression are not 
dependent solely on cancer cells, but also critically on the nature of interaction 
between them and the surrounding milieu, including tissue microvasculature, 
growth factors and extracellular matrix (ECM).  
 First, a simple, economical, and high-throughput method for concave 
microwell prototyping on a conventional culture dish was introduced to reliably 
generate the multicellular cancer aggregates (MCAs) for further device 
integration. Microwells generated by CO2 laser ablation on polystyrene (PS) 
exhibited the best surface smoothness and cavity contours among all materials 
tested. Microwells were generated with diameter ≈250 μm. A549 lung 
adenocarcinoma MCAs were successfully generated in PS microwells in four 
days, and aggregate size could be controlled at ≈80 μm.  
The second part of this thesis describes preclinical therapeutic anti-
cancer drug screening performed to identify the effective dosage for 2D and 3D 
conditions. MCAs were utilized in a microfluidic platform with co-culture of 
human umbilical vein endothelial cells (HUVECs) validating our 3D drug 
screening assay. Results confirmed the importance of growing cells in 2D vs. 
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3D and that other cell types, in this case endothelial cells, can significantly alter 
the levels of drug required to inhibit MCA dissemination.  
Next, a modified microfluidic co-culture platform was designed with 
improved HUVEC monolayer growth. Lung A549 and bladder carcinoma T24 
MCAs were tested. Dose-response assays of four drugs were validated 
according to their invasive capability to the adjacent 3D matrix. In the absence 
of HUVECs, T24 MCAs showed dramatic spontaneous dissemination as 
compared to A549 MCAs. T24 MCA dispersion inhibition required higher 
doses of drugs as a single agent and lead to only partial inhibition at 10 µM 
concentration with a Src inhibitor AZD-0530. Near complete inhibition was 
obtained only when 4 drugs CI-1033, MK-2206, A83-01, AZD-0530 were 
added in combination at a 10µM concentration. However, the efficacy of this 
near complete inhibition forfeited in the presence of HUVECs for T24 cells. 
The enhanced dispersal observed in the presence of HUVECs is a consequence 
of the secretion of growth factors including HGF and FGF-2 by endothelial cells. 
Growth factor production was not affected by addition of AZD-0530. Overall, 
the above systems demonstrated a new approach in drug screening with the 
potential to better replicate the in vivo microenvironment. This platform 
provides a new basis for understanding the progression of carcinoma towards 
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Table 1. Targeted inhibitors and doses used in this study. Effective dose 
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List of Figures   
Figure 2-1. Schematic diagram of the microwell fabrication process for 
generation of 3D aggregates. (a) Illustration of laser ablation process. Substrate 
is melted by CO2 laser energy distributed in a Gaussian profile. The ablation 
leaves a concave well with a recast zone at its edge. (b) Laser drilling via an 
XY mobile focus carriage traveling to the location of interest. (c) A thin layer 
of pluronic was deposited to prevent cell attachment on the substrate. (d) Cell 
seeding. (e) Formation of aggregates after 4–5 d. 
Figure 2-2. Schematic and photograph of a 3D co-culture microfluidic device. 
(a) Schematic diagram of device layout depicts the inlets for injecting cells, 
filling collagen, and replenishing medium. (b) Enlarged view of gel region and 
the HUVEC-lined channel. Cytokines in conditioned medium from the 
HUVEC monolayer diffuse into the gel region triggering MCAs to undergo 
EMT. (c) Photograph of the PDMS-molded device bonded on a glass cover-
slip. 
Figure 2-3. Schematic illustration of an improved microfluidic co-culture 
platform for drug screening. (a) Schematic diagram of the device design depicts 
the layout of the media channels and gel regions. In the new design, four main 
microfluidic channels were arranged by two middle gel regions and two media 
channels located on both sides. Similarly, media channels were used for 
introducing culture medium and HUVECs. One of the gel regions was used to 
place MCA-embedding collagen gel. (b) Photograph of the PDMS device is 
displayed for the appreciation of geometrical arrangement. (c) An enlarged 
isometric view of the device showing the relative locations of co-culturing 
MCAs and HUVECs. Plain collagen gel was introduced to 1st gel region and 
waited for heat polymerization. Once this gel barrier was made, fibronecting-
containing solution was deposited in the media. The HUVECs introduced from 
media port was then placed for seeding 4—6 h, to allow sufficient cell 
attachment and better control of number of cells attached. (d) HUVECs 
monolayer formed after 4 h and 36 h, respectively, in the microfluidic channel. 
VE-cadherin staining demonstrates the cellular junctions were formed. At 4 h, 
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cells were settled on glass with some cells growing on collagen. After 36 h, 
HUVECs can further grow from bottom glass to top PDMS chamber surface. 
Green: VE-cadherin; blue: nuclei. (e) Diffusive concentration profiles of 
fluorescent dextran introduced from which permeability can be quantified. The 
quantification was performed after 36 h of HUVEC seeding, in attempt to 
simulate the diffusive profiles of a drug diffusing through monolayer. (f) Drugs 
used in this study, with the targeting pathways and stage of development. 
Figure 3-1. Preliminary testing of the depth of microwells corresponding to 
power (column) and scanning speed (row) required. Testing power ranging 
from 1 Watts to 5 Watts, and scanning speed from 25 mm s-1 to 125 mm s-1 
were instigated. Microwell structures were acquired from PDMS replica 
molding casted on PS microwells ablated by laser energy. White dotted lines 
are of separating reflection plane for clarity. 
Figure 3-2. Characterization of microwells on PMMA, PDMS, and PS. (a) 
Representative microwell features with respect to a range of laser power from 
1–5 W. For clarity, the reflection plane is indicated in white dotted line. (b) 
Evaluation of diameter, depth, and aspect ratio of microwell in different 
materials. 
Figure 3-3. Isometric-view SEM images of microwells from three materials. A 
detailed surface profile of a single microwell is presented (middle), along with 
a negative formed by PDMS replica molding (right). (a–c) PMMA microwells 
exhibit a rough surface at the periphery and have micropores distributed over 
much of the internal surface. (d–f) PDMS microwells exhibit a smooth surface 
and a cone-shaped bottom. (g–i) PS microwells have smooth surface 
characteristics with substantial recast material around the edge and gentle 
curvature at the bottom. 
Figure 3-4. Generation and characterization of MCAs. (a–c) Cell cultures are 
shown 1, 2, and 5 d after seeding. MCAs formed within 5 d. (d) SEM image 
illustrating the location of an MCA in a PS microwell. (e) Higher magnification 
SEM image of an MCA reveals the surface properties. The majority of cells 
clumped into a compact aggregate without distinct cell–cell interface indicating 
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maximized intercellular adhesion. (f) CMFDA live cell staining indicated good 
cell viability and illustrates the shape of the MCAs. (g) Size correlation 
between MCAs and different cell seeding concentrations in M1 and M2 
microwells. (h) Probability of MCA formation across different cell seeding 
densities in M1 and M2 microwells. 
Figure 3-5. Top-view bright field micrographs of 5 by 5 M1 and M2 PS 
microwell arrays with 500 μm distance between microwells. (a) M1 microwell 
arrays shown in black circles. Each microwell surrounds by an outer bright ring 
shape due to the reflection from recast zone. (b) M2 microwells demonstrate a 
more elliptical shape and brighter spots residing at the edge of the microwells.  
Scale bar: 200 μm 
Figure 3-6. Illustration on MCA migration in 2D and 3D conditions using 
microtiter plate over 24 h. (a) Schematics of MCAs placing on 2D surface. 
MCAs were put in contact directly with microtiter 96-well substrate. Each well 
contains ≈10-20 MCAs randomly distal from one another. Dispersion was 
initiated from the contact surface between MACs and substrate. (b) Time-lapse 
tracking of MCA dispersing in 2D. Single cells were tracked over 24 h, 
displaying consistent outward directional migration. (c) Phase-contrast image 
of an MCA spreading in 2D for 8 h while the MCA maintained cell-cell contact. 
(d) The same MCA dispersing for 24 h in 2D. Cell movement translated from 
collective cell migration to single cell migration. (e) Schematics of MCAs 
embedding in 3D native type I collage. The microtiter plate was placed upside-
down during gel cross-linking to ensure MCAs suspended in 3D.  (f) Time-
lapse tracking of MCA dispersing under 3D condition. (g) Phase-contrast 
image of early invasion of an MCA dispersing in 3D collagen. Early invasion 
was observed through formation of pseudopodia at 2 h, indicated by arrows. 
(h) The same MCA broke up after 24 h, and a single escaped cell was observed 
(indicated by the arrow). 
Figure 3-7. Spreading of precursor films of MCAs on a 2D plane substrate. (a) 
Spreading area of precursor films with different sizes of MCAs. Blue: without 
EGF; red: 20ng EGF-added. The area of spreading is correlated with the size 
of MCAs. (b) Evolution of precursor films with time. The dissipation energy is 
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sought to be relevant to the cell-cell intracellular adhesion energy. EGF 
addition triggered MCAs to become dispersal compared to the control. 
Figure 3-8. Screening of EGFR inhibitor onA549 MCA in 2D and 3D 
conditions using microtiter 96-well plate. Representative time-lapse intervals 
show MCA dispersion across different concentrations of drugs CI-1033 at 2, 8, 
16, and 24 h. Presentation of both (a) 2D conditions and (b) 3D conditions were 
scaled to the same range. Both the highest and the lowest dosages for 2D 
conditions are 1 order of magnitude larger than that of 3D conditions. 
Figure 3-9. Dose-response assays on A549 MCAs. Both 2D and 3D dispersion 
were performed utilizing A549 MCA in the microtiter plate setup. Drug effect 
of CI-1033 was evaluated after 24 h. 
Figure 3-10. 3D fluorescent images of the co-culture microfluidic drug 
screening assays. Time-series of each A549 MCA dispersion in the collagen 
matrix was captured at 0 h, 12 h and 36 h. (a) A549 MCA monoculture in 3D 
collagen without HUVECs monolayer over three timepoints. MCA remained 
intact throughout 36 h, where triangles depicting the PDMS pillars on the edge 
of collagen. (b) Co-culture of HUVEC monolayer and A549 MCA in the 
microfluidic device. A549 gradually dispersed over the course of 36 h. (c) CI-
1033 addition to the co-culture microfluidic in the presence of the HUVECs. 
Adding EGFR inhibitor reversed MCA dispersion induced by HUVECs. Red: 
nuclei of A549 cells; green: HUVEC. 
Figure 3-11. Quantitative analysis of drug screening on MCA dispersion and 
proliferation in the microfluidic device in the presence of HUVECs at 36 h. (a) 
Normalized dispersion for twelve inhibitors and one control. (b) Representative 
normalized dispersion performed utilizing AZD-0530, a Src inhibitor, with 
three concentrations over three timepoints, at 0 h, 12h and 36 h. (c) Normalized 
proliferation for twelve inhibitors and one control. (d) Representative 
normalized proliferation performed utilizing AZD-0530 with three 
concentrations over three timepoints, at 0 h, 12h and 36 h. The concentration 
of each drug was optimized to discern MCA inhibition. The effective 
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concentrations for full inhibition for twelve inhibitors are summarized in Table 
1. 
Figure 3-12. Normalized cell dispersion and corresponding cell number at 36 h. 
Four quadrants were defined to characterize the dose response for each drug. 
The upper right quadrant indicates cases with high rates of proliferation and 
dispersion, where we find the control conditions. Most drug-treated data lie in 
the lower left quadrant with low proliferation and low dispersion activity. 
Therefore, it appears that for the conditions tested, drugs reduced cell 
dispersion and cell proliferation simultaneously. 
Figure 3-13. Immunostaining of EMT markers on A549 MCAs at 0 h and 36 h 
in co-culture with HUVECs in the microfluidic platform. (a-b) Expression of 
vimentin in MCAs at 0 h. MCA was intact with little expression of vimentin. 
(c-d) Expression of vimentin in MCAs at 36 h. MCA was dispersed with high 
expression of vimentin at 36 h. Blue: nuclei; green: vimentin. (e–h) High 
expression of E-cadherin in MCAs was at 0 h. After co-culture with HUVECs 
for 36 h, the MCA dispersed and expression of E-cadherin disappeared. Blue: 
nuclei; green: E-cadherin. 
Figure 3-14. Evaluation of drug effects on HUVEC monolayer growth. (a) and 
(b) Representative fluorescence images of HUVEC monolayers in the presence 
of drug LY 364947 at 0 h and 36 h, respectively. (c) Plots of normalized 
HUVEC cell number for each compound at the highest dose used in this study. 
Normalized cell number is the ratio of cell number at 36 h to that at 0 h. 
Figure 3-15. Screening therapeutic drugs on A549 aggregates over 36h. (a) 
Staining of EMT markers E-cadherin and vimentin in A549 aggregates at 0h 
and 36h. Green: E-cadherin/vimentin; blue: DAPI-stained nuclei. (b) 
Normalized dispersion and cell number measured for three concentrations with 
four drugs (MK-2206: Akt inhibitor; AZD-0530: Src inhibitor; A83-01: TGF-
βR inhibitor; CI-1033: EGFR inhibitor). (c) Normalized dispersion measured 
over time for analysis synergistic effects between CI-1033 and MK-2206, at 
four different concentrations. 
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Figure 3-16. Screening therapeutic drugs on T24 aggregates over 36h in the 
presence/absence of HUVECs. (a) Staining of EMT markers E-cadherin and 
vimentin in T24 aggregates at 0h and 36h. Green: E-cadherin/vimentin; blue: 
DAPI-stained nuclei. (b) Normalized dispersion of T24 cells with four drugs, 
in the absence of HUVECs. (c) Normalized dispersion of T24 cells with four 
drugs, in the presence of HUVECs. (d) Comparison of normalized dispersion 
between control and AZD-0530 treated group, in the presence/absence of 
HUVECs. (e) Qualitative images of the four groups at 0h and 36h, respectively. 
Figure 3-17. T24 cellular response to drug synergistic doses. Normalized 
dispersion measured over time for synergistic effect analysis of four drugs, with 
every two drugs in combination. All results showed significant deduction of 
dispersion to half compared to control. However, dispersion was still observed 
and inhibition among different combinations was insignificant. 
Figure 3-18. Drug combination analysis on T24 cell aggregates. (a) Qualitative 
images showing the effect of drug used in combinations of four, in the presence 
or absence of HUVECs at various doses. (b) Comparison between AZD-0530 
and drugs in combinations of four, in the presence or absence of HUVECs at 
various doses.  Concentrations given are for each drug individually (e.g. 
combined 5μM means each drug used at a concentration of 5μM) 
Figure 3-19. Representative images of MCA dispersion induced by growth 
factors in the presence of Src inhibitor (AZD-0530). Growth factors of TGF-
β1, TGF- β3, EGF, FGF, HGF and PDGF were used to simulate section from 
HUVECs. Addition of growth factors could either slightly or fully restore T24 
dispersion. In the cases of FGF(FGF-2) and HGF are two to induce the highest 
dispersion among other growth factors. 
Figure 3-20. Analysis of endothelial cell secretion of HGF and FGF-2 in co-
culture or by T24 cells alone. (a) ELISA measurement of FGF-2 concentration. 
(b) ELISA measurement of HGF concentration. (c) Neutralized antibody 
blocking experiment (HGF and FGF-2). 
Figure 3-21. Schematic and device photo of a multiplex co-culture microfluidic 
system. The design consists of 15 media channels and 14 gel channels. Each 
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condition comprises of three media channels comprised of two gel channels, 
allowing two replicates in one condition. With this arrangement, up to 7 
conditions could be screened on one chip, which is in equivalent to combining 
14 devices into one. Stitched fluorescent images showing two gel channels 
separated by a media channel. Each gel channel contained multiple MCAs at 
indicated time-points. Scale, 1 mm. 
Figure 3-22. Screening on T24 MCA using automated imaging across 7 gel 
channels. (A) Upper, stitched images of gel channel with indicated 
concentration. T24 MCA were screen with AZD-0530, as previously proven 
effective to alleviate T24 MCA dispersion in the absence of HUVECs. MCA 
dispersion was analyzed by determining the outline of the MCA. (b) Dose-
response analysis based on the number of pixels each MCA occupied. 
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Chapter 1 Introduction 
1.1 Background 
Overall, 80% of cancers are epithelial in origin and these epithelial cancers (or 
carcinoma) (Bissell and Radisky 2001) often progress into more invasive forms, 
leading to metastasis, where cancer cells disseminate from the primary tumor to 
colonize distant tissues to form secondary tumors (Bravo-Cordero, Hodgson et 
al. 2012). Of the 8.2 million people worldwide who died from cancer in 2012, 
metastatic tumors were responsible for 90% of these cancer related deaths 
(Siegel, Naishadham et al. 2012). 
The metastatic process of carcinomas involves multiple steps with 
precise coordination of cancer cells and biologic signaling. In early metastasis, 
epithelial to mesenchymal transition (EMT) is believed to be an important 
mechanism that allows tumor cells to gain metastatic potential for invasion and 
intravasation(Thiery 2002). This transition transforms carcinoma cells to a more 
migratory and invasive phenotype mainly by reducing their ability for cell-cell 
adhesion. Accompanied by degradation of extracellular matrix (ECM) and 
penetration through the basement membrane, these cells are able to intravasate 
into adjacent vascular and lymphatic systems. Finally, these tumor cells 
translocate through these circulating systems to colonize distant organs. While 
the metastatic process has been extensively studied, most cancer patients still 
suffer from poor prognosis and high mortality. Therefore, a new strategy that 
targets the prevention of metastasis could be impactful for increasing overall 
survival in cancer patients.  
1.2 In vitro tumor invasion and migration assays 
Initially anticancer drug discovery programs predominantly focused on 
the search for agents that inhibit unrestrained cellular proliferation. This 
included application of cytotoxic chemotherapy, which allows killing of rapidly 
dividing cells by targeting DNA replication. However, this treatment often also 
leads to damage to normal rapidly dividing tissues such as bone marrow, skin 
and gut (Zimmermann, Box et al. 2013). Therefore, aside from simply targeting 
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hyper-proliferating cells, new anti-cancer approaches have taken into 
consideration other unique hallmarks of cancer cells that may be used to 
selectively target them against normal tissue cells (Hanahan and Weinberg 
2011). The enhanced cell motility of malignant tumor cells was studied for use 
in a drug target strategy that could be effectively combined with conventional 
cytotoxic drugs to enhance overall anti-metastatic effects (Melisi, Troiani et al. 
2004).  
Cell motility is regulated by extracellular signals in the 
microenvironment and is integral to many key processes in developmental 
biology, physical and pathological conditions (Eccles, Box et al. 2005). 
Utilizing different cell motility, tumor cells may shift from one form to another 
depending on the environment and may thus escape from inhibitors by virtue of 
this means. For example, tumor cells may leverage alternate models of motility 
for invasion by protease-independent mechanisms such as amoeboid migration 
whereby cells squeeze through collagen-lined pores, or to degrade ECM by 
secreting proteolytic enzymes (Huttenlocher and Horwitz 2011). Therefore, 
developing the proper in vitro functional assays with an appreciation of how 
tumor cells specifically move within tumor microenvironments could improve 
target validation and drug evaluation studies.  
  One popular approach to measuring cell migration is the ‘wound 
healing’ assay, in which a band of confluent adherent cells is manually removed 
by mechanical force. The subsequent process of cell migration from the intact 
cell layer can be monitored by time-lapse imaging to evaluate the invasiveness 
of the cells under different drug treatments (Yarrow, Perlman et al. 2004). 
Transwell and Boyden chambers are also conventional tools to evaluate cell 
invasiveness. In this method, an upper chamber is separated from the lower 
chamber by a semi-permeable membrane, and cells are added to the upper 
chamber. Chemo-attractant diffusing from the lower chamber can be used for 
testing chemotaxis by quantifying the number or rate at which cells migrate 
through the pores (Albini and Noonan 2010). Modification to this method 
allows not only 2D but also invasion in 3D ECM such as MatrigelTM (Albini 
and Noonan 2010). 
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Although these methods offer simplicity in use and are commercially 
available, in vitro assays used for screening anti-metastatic compounds, 
however, should replicate as close as possible the in vivo tumor 
microenvironment, as the pathophysiology of cancer and mechanisms driving 
tumor progression are not dependent solely on tumor cells, but also critically on 
the nature of interaction between them and surrounding milieu, including tissue 
microvasculature, growth factors and ECM. Mimicking physiological cancer 
microenvironments and tumor 3D structure may be important in the study and 
prevention of the various processes in metastasis, including cancer cell 
undergoing EMT into more migratory types and invasion into proximal tissues.  
     
1.3 In vitro 3D multicellular model  
Three-dimensional (3D) tissue-like cultures are now widely used as in 
vitro models of in vivo cellular functions such as embryonic development, 
wound-healing, and malignancy. Compared to a two-dimensional (2D) 
monolayer culture, a 3D model better mimics the in vivo tissue-like cellular 
features in morphology, cell-cell interaction, signal transduction and 
mechanical stimulation, thus providing a physiologically and pathologically 
relevant environment (Wolf, Wu et al. 2007; Wendt, Riboldi et al. 2009). 
Multicellular 3D aggregates have proven useful as a model for directing specific 
cell lineages using embryonic stem cell-formed embryoid bodies (Hwang, 
Chung et al. 2009), and studying collective cell migration in cancer (Friedl and 
Gilmour 2009). 
Research on multicellular cancer spheroids (MCSs) or aggregates 
(MCAs) has resulted in new insights into the processes of cancer metastasis. 
These MCAs share common features with carcinoma in vivo and provide a 
better platform for studying chemo- and radio-resistance of tumors. One 
example is the screening of therapeutic drugs via cancer cell-formed MCAs 
(Hakanson, Textor et al. 2011; Aref, Huang et al. 2013). In particular, 
considering that cancer metastasis is initiated by cell dispersion from a solid 
tumor (Chambers, Groom et al. 2002), which is a typical feature of epithelial-
mesenchymal transition (EMT) (Thiery 2002; Thiery, Acloque et al. 2009), 
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recapitulating cell dispersion from multicellular aggregates provides a 
potentially useful in vitro model in the search for drugs that inhibit cancer cell 
delamination (Aref, Huang et al. 2013).  
There are several established systems for culturing multicellular 
aggregates. A widely utilized class of methods is stationary suspension culture, 
e.g. non-adherent surface, spinning dish/flasks (Castaneda and Kinne 2000), or 
hanging drop methods (Tung, Hsiao et al. 2011), for ease of aggregate 
generation. However, the disadvantage of these methods is that a non-adherent 
surface fails to control aggregate size precisely. Additionally, spinning dish 
methods may pose detrimental levels of shear stress to delicate cell lines such 
as embryonic stem cells (ESCs). Hanging drop methods can grow aggregates 
with consistent size; however, scaling up the number of aggregates is 
cumbersome, and changing media without disturbing aggregates can be difficult. 
Furthermore, acquisition of time-lapse images for a particular aggregate is a 
challenge. 
Given recent advances in microfabrication technology, microwells have 
become a viable alternative, providing a high-throughput method of culturing 
size-controllable cell aggregates (Kloss, Fischer et al. 2008; Choi, Chung et al. 
2010; Zorlutuna, Annabi et al. 2012). In general, a non-adhesive substrate with 
defined microstructure is used to isolate cells and allow them to cluster and 
grow into compact multicellular aggregates through cell-cell adhesion. This 
arrangement allows convenient observation of each aggregate and change of 
medium. Chips fabricated by soft lithography can also be used to control the 
distribution of cells and grow aggregates in a lab-on-a-chip platform (Ong, 
Zhang et al. 2008; Wlodkowic, Faley et al. 2009; Kim, Lee et al. 2011).  
Laser fabrication offers an alternative to lithography-based approaches for 
microfabrication, but application of this technique to create microwells is 
relatively rare (Chen, Liu et al. 2007; Napolitano, Chai et al. 2007; Chen, Tu et 
al. 2009; Young, Berthier et al. 2011). Current microwell approaches based on 
lithographic fabrication require either chemical etching with special equipment 
and cleanroom facilities or a silicon master for replica molding. From an 
economic perspective, even minor changes in the design require a cumbersome 
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and laborious process accompanied by a significant increase in the cost of 
fabrication and materials. Recent studies using 3D laser printing (Napolitano, 
Chai et al. 2007) or CO2 laser ablation (Selimovic, Piraino et al. 2011) in 
microwells attempted to minimize fabrication complexity; however, in these 
studies an accessory bonding (Selimovic, Piraino et al. 2011) or replica molding 
(Napolitano, Chai et al. 2007) process was still needed. Furthermore, irregular 
microwell shapes with rough structures were observed (Selimovic, Piraino et al. 
2011), which may potentially be harmful to cell growth. 
 
1.4 Microfluidic technology and application in drug discovery 
Over the last decade, microfluidic platforms have been leveraged in many 
different cell culture applications (Chen, Tu et al. 2011; Shin, Han et al. 2012). 
It has been employed in a number of different cell culture applications, with 
advantages in creating a precisely controlled geometrical, physical and 
biochemical microenvironment for cells (Tourovskaia, Figueroa-Masot et al. 
2005; El-Ali, Sorger et al. 2006).  
More recently, methods have been introduced to incorporate multiple cell 
types in co-culture, simultaneous cell growth on 2D surfaces and in 3D scaffolds, 
and control of a variety of biochemical and biophysical factors while providing 
the capability for real-time imaging with standard microscopy. These methods 
have been used to study, for example, cancer–endothelial cell interactions 
(Chung, Sudo et al. 2009), liver cell growth (Toh, Zhang et al. 2007), 
biochemical gradient-guided cell growth (Vickerman, Blundo et al. 2008; 
Kothapalli, van Veen et al. 2011), and migration (Shamloo and Heilshorn 2010), 
and to simulate certain aspects of organ function (Sudo, Chung et al. 2009). 
While this technology shows promise in a variety of settings, it has not yet been 
used to examine carcinoma dissemination, and requires further development 
before it can be applied to the quantitative assessment of metastatic potential at 
the molecular and cellular level. 
Studies have also been introduced to employ microfluidics in drug 
screening applications because microfluidics can potentially facilitate medium 
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and reagent exchange in a rapid and convenient fashion (Tsui, Lee et al. 2013). 
Drug screening assays can easily performed within the microfluidic setup with 
the nature of channel design. The microfluidic chips can be integrated into a 
much larger drug-screening ecosystem that allows full automation of media 
change and liquid handling thorough tubing and pumps; such a set-up is highly 
relevant to drug-screening needs in industry, as thousands of compounds are 
screened simultaneously. Furthermore, the microfluidic design also requires 
minimal consumption of expensive compounds, thus reducing the cost of each 
screening step.   
 
1.5 Objectives of the study 
Based on above reasoning, a rapid and economical strategy was presented 
for creating concave microwells in conventional culture dishes for generating 
3D MCAs. To demonstrate the utility of this approach, these MCAs were used 
for screening anti-cancer drug compounds. A CO2 laser that directly “writes” 
microwell structures was used with the desired diameter and depth in less than 
a second. Microwell patterns produced by CO2 laser ablation were studied on 
three types of conventional substrates, namely polymethylmethacrylate 
(PMMA), polydimethylsiloxane (PDMS), and polystyrene (PS). Microwell 
diameter and depth, geometry, and surface roughness were all considered in 
order to identify the most suitable material for generating microwells. To 
validate our microwell system for generating an in vitro 3D tumor model, the 
formation of MCAs using a human lung cancer cell line (A549) was 
characterized under different cell seeding concentrations.  
Furthermore, the 3D tumor model MCA was incorporated to a 
microfluidic system. This system demonstrates a tumor microenvironment 
model based on a microfluidic device capable of 1) recapitulating the physical 
and biochemical context that allows for the manifestation of cancer invasion in 
3D, in the presence of human endothelial cells; and 2) quantitatively monitoring 
the MCA dispersion inhibitory effect of drugs. MCAs transferred to and grown 
in this device were induced to disperse in 3D and exhibit mesenchymal 
morphology in a short timeframe, during co-culture with human umbilical vein 
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endothelial cells (HUVECs) without direct cell-cell contact. Drugs that block 
specific signaling pathways introduced to the HUVEC-lined channel beside the 
MCA-seeded collagen gel were shown to behave differentially in 3D than in 2D, 
and interact strongly with the endothelial monolayer.  These effects were shown 
to have a significant impact on the concentration of drug needed to inhibit MCA 
dispersion.   
The aim of this thesis was to establish a complete method for the 
development of a 3D carcinoma model, and further incorporate this model with 
microfluidic co-culture system to investigate the prevention of MCA 
delamination for drug screening applications. The specific aims of the studies 
were:  
 To develop a simple and rapid method to form a 3D cancer 
model. 
 To establish a microfluidic co-culture system that could 
incorporate the 3D cancer model for drug screening.  
 To identify drugs as a single agent or in combinations to prevent 
lung and bladder carcinoma dissemination.  
 To develop a multiplex microfluidic system that has the potential 
for high-throughput screening.   
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Chapter 2 Materials and Methods 
2.1 Microwell prototyping 
Microwell prototyping was implemented using a commercial air-cooled 10.6 
μm CO2 laser engraving/cutting system (VLS-2.30, Universal Laser System Inc., 
USA) with high power density focusing optics and maximum output power of 
10 W. The focused laser beam was operated in TEM00 mode, ablating the 
material surface to directly pattern the substrate of interest. Laser energy was 
capable of heating all tested surfaces sufficiently to melt and gasify. The melted 
surface was purged by laser pressure in a Gaussian distribution producing a lip 
around the circumference of the ablated zone and a concave well-like space in 
the middle suitable for cell docking (Figure 2-1a). Wells were characterized by 
their top opening width W and top-to-bottom depth, D. 
 
Figure 2-1. Schematic diagram of the microwell fabrication process for 
generation of 3D aggregates. (a) Illustration of laser ablation process. Substrate 
is melted by CO2 laser energy distributed in a Gaussian profile. The ablation 
leaves a concave well with a recast zone at its edge. (b) Laser drilling via an XY 
mobile focus carriage traveling to the location of interest. (c) A thin layer of 
pluronic was deposited to prevent cell attachment on the substrate. (d) Cell 
seeding. (e) Formation of aggregates after 4–5 d. 
 
Multi-well patterns were designed using commercial software (AutoCAD 
2007, Autodesk Inc.) and transferred to the laser system. Patterns used for the 
present study contained 100 × 100 microwell arrays spaced 0.5 mm by 0.5 mm. 
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Laser scanning was performed by a XY mobile Focus Carriage (FC) traveling 
to the location of interest (Figure 2-1b). The characteristics of these microwells 
were assessed with the combinations of laser power and scanning speed on PS 
material. With a desired laser output, microwells were generated on PMMA (1 
mm thick), PDMS (2 mm thick, Sylgard 184, Dow Corning), and PS (1 mm 
thick, 90 mm untreated tissue culture dish, VWR). Microwells were washed 
with 70% ethanol for both disinfection and bubble removal, and then washed 
twice with PBS to replace the ethanol and to clean debris from laser fabrication. 
The fabricated PS microwells were preserved in PBS solution before use. 
 
2.2 Cell culture  
A549 human lung adenocarcinoma epithelial cells transfected with histone 
H2B-mCherry cDNA for nuclear staining and T24 human urinary bladder 
transitional cell carcinoma were cultured in a T75 flask (Nunclon Surface) in 
Dulbecco's modified Eagle medium (Gibco/Invitrogen 12100) supplemented 
with 10% fetal bovine serum (Gibco/Invitrogen), 1% penicillin-streptomycin. 
Puromycin 1 µg mL-1 (Sigma-Aldrich, St. Louis, MO, USA) was added for the 
selection of A549 mCherry–expressing cells, along with the medium change 
every 36 h to 48 h. Human umbilical vein endothelial cells (HUVEC) (Lonza, 
Basel, Switzerland) were maintained in microvascular endothelial growth 
media (Lonza EGM-2MV, Basel, Switzerland), i.e., Endothelial Basal Media-2 
(EBM-2) supplemented with SingleQuotss including 5% (25 mL per 500 mL 
bottle) FBS, 1% penicillin-streptomycin and hydrocortisone 0.2 mL, hFGF-B, 
0.2 mL; vascular endothelial growth factor (VEGF), 0.5 mL; R3-IGF-1, 0.5 mL; 
ascorbic acid, 0.5 mL; heparin, 0.5 mL; hEGF, 0.5 mL; and GA-1000, 0.5 mL.  
For passage, cells at 80–90% confluency were detached from the culture 
flask by treating with 0.05% trypsin–ethylenedinitriletetraacetic acid (Trypsin–
EDTA) (Sigma-Aldrich, St. Louis, MO, USA) at 37 ºC in an incubator for 3 
min. Medium was then added to inhibit the enzymatic reaction of Trypsin-
EDTA. Sub-culture seeding density was kept at 2–3 × 105 cells mL−1 in a T75 
flask. We prepared two different types of EGM-2MV, one with VEGF and the 
other without. The one with VEGF was used to maintain the HUVEC culture, 
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while the other one is applied in seeding HUVEC in the devices, to prevent 
unwanted exogenous VEGF degradation of the collagen gel. 
 
2.3 Generation of multicellular cancer aggregates 
PS microwells were coated with a layer of anti-adhesive repellent using PBS 
with 0.2% pluronic (Pluronic F108, BASF) for 1 h (Figure 2-1c) (Liu, Jastromb 
et al. 2002; Kuo, Chiang et al. 2012). Subsequently, the coated microwell plate 
was washed twice with PBS to minimize free polymers in the plates (Wong and 
Ho 2009). The pluronic coating has been shown to stably repel cell attachment 
for ≈1 week during cell culture incubation (Corey, Gertz et al. 2010). A549 and 
T24 cell suspensions, detached using the aforementioned procedure for passage, 
were mixed with culture medium (10 mL) and then added into the dish. After 
incubation for 1 h, cells that had not embedded inside each microwell were 
removed by exchanging with 10 mL of fresh medium (Figure 2-1d) (Choi, 
Chung et al. 2010). Culture medium containing 0.01% puromycin was changed 
every 4 d. Cells embedded in each microwell form aggregates through cell–cell 
while they are in suspension (Figure 2-1e). Multiple MCAs were generated from 
a conventional culture dish comprising a microwell array. 
 
2.4 Microfluidic device designs 
2.4.1 Design I: One-gel device 
The microfluidic tissue culture devices used in this study are described in detail 
by Farahat et al (Farahat, Wood et al. 2012). The devices consist of 2 media 
channels running parallel to and located on either side of an extended central 
region containing the extracellular gel matrix, all formed by bonding a coverslip 
to a patterned polydimethylsiloxane (PDMS) substrate. By varying the 
composition of the growth media in the channels, drugs, growth factors or other 
agents can be introduced, either at uniform concentration or as a gradient across 
the gel region, to elicit cellular responses. MCAs or individual cell behavior can 
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be observed via 3D confocal imaging of the gel region through the supporting 
glass coverslip. 
 
Figure 2-2. Schematic and photograph of a 3D co-culture microfluidic device. 
(a) Schematic diagram of device layout depicts the inlets for injecting cells, 
filling collagen, and replenishing medium. (b) Enlarged view of gel region and 
the HUVEC-lined channel. Cytokines in conditioned medium from the HUVEC 
monolayer diffuse into the gel region triggering MCAs to undergo EMT. (c) 
Photograph of the PDMS-molded device bonded on a glass cover-slip. 
 
2.4.2 Design II: Two-gel device 
The microfluidic design incorporated two different 3D collagen compartments 
between the two media channels. The MCAs can be introduced in the 
compartment distal to the channel in which endothelial cells assemble to mimic 
the vascular well (Figure 2-3a and c). Similar to the previous design, the control 
of chemical composition in the fluidic channels can be obtained, in either at 
uniform concentration or as a gradient across the gel region, to elicit cellular 
responses. Besides, the new design facilities adding different cell types in the 
new collagen compartment. High-content confocal imaging can also be 




Figure 2-3. Schematic illustration of an improved microfluidic co-culture 
platform for drug screening. (a) Schematic diagram of the device design depicts 
the layout of the media channels and gel regions. In the new design, four main 
microfluidic channels were arranged by two middle gel regions and two media 
channels located on both sides. Similarly, media channels were used for 
introducing culture medium and HUVECs. One of the gel regions was used to 
place MCA-embedding collagen gel. (b) Photograph of the PDMS device is 
displayed for the appreciation of geometrical arrangement. (c) An enlarged 
isometric view of the device showing the relative locations of co-culturing 
MCAs and HUVECs. Plain collagen gel was introduced to 1st gel region and 
waited for heat polymerization. Once this gel barrier was made, fibronecting-
containing solution was deposited in the media. The HUVECs introduced from 
media port was then placed for seeding 4-6 h, to allow sufficient cell attachment 
and better control of number of cells attached. (d) HUVECs monolayer formed 
after 4 h and 36 h, respectively, in the microfluidic channel. VE-cadherin 
staining demonstrates the cellular junctions were formed. At 4 h, cells were 
settled on glass with some cells growing on collagen. After 36 h, HUVECs can 
further grow from bottom glass to top PDMS chamber surface. Green: VE-
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cadherin; blue: nuclei. (e) Diffusive concentration profiles of fluorescent 
dextran introduced from which permeability can be quantified. The 
quantification was performed after 36 h of HUVEC seeding, in attempt to 
simulate the diffusive profiles of a drug diffusing through monolayer. (f) Drugs 
used in this study, with the targeting pathways and stage of development. 
 
2.5 Device fabrication and cell seeding in a 3D matrix 
Detailed device fabrication and operation process can be found in Appendix B. 
The devices were fabricated in PDMS (Dow Corning Sylgard 184) at a ratio of 
10:1 polymer to cross-linker using standard soft lithography techniques 
(Whitesides and Massachusetts Institute of Technology. Microsystems 
Technology 1998). Devices were autoclaved in DI water for 20 min followed 
by a dry autoclave cycle for 20 min and baked overnight at 80 C to dry. Glass 
cover slips (#1.5 Cell Path, UK) were then plasma bonded to the PDMS 
substrate that had been pretreated with ethanol and dried. All device channels 
were then treated with 1 mg mL-1 poly-D-lysine (PDL) solution (Sigma-Aldrich, 
USA) for 4 h to enhance cell and collagen matrix binding to PDMS (Shin, Han 
et al. 2012), followed by another round of drying at 80 C for 24–48 h to make 
the devices hydrophobic. 
200 μL collagen gel solution at 2.5 mg μL-1 and pH 7.4 was prepared on 
ice with 126.1 μL type I collagen (3.87 mg μL-1, BD Biosciences Cat. No. 
354236), 20 mL PBS (10 Χ) with phenol red (Gibco/Invitrogen 14080-055, 
USA), 43.1 μL deionized water, 7 μL NaOH (0.5 N), and 20 μL cell suspension 
medium with 30–50 MCAs. The specific gel composition was decided upon 
through a set of preliminary experiments in which we sought a balance between 
rapid matrix degradation by endothelial cells for low collagen concentrations 
and impaired cancer cell migration at high concentrations. MCA-containing 
collagen gel solution was then pipetted into the central gel region at low 
pressure to avoid spillage into the side channels. Gel is confined to the central 
gel cage by means of surface tension. Once in place, collagen gel solution was 
kept in a humidity box at 37 °C for 40 min to allow gel polymerization via 
thermal cross-linking. DMEM and EGM-2MV with HUVECs were 
subsequently introduced to respective media channels. After 1–2 h, HUVECs 
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attached to the endothelial cell growth channel and formed a semi-confluent 
monolayer on the coverslip bottom substrate and onto the gel surface. The 
conditioned medium produced by HUVEC secretions diffused into the adjacent 
collagen gel. Average distance between the HUVEC and tumor MCAs was 200 
μm, facilitating rapid cell–cell signaling. 
 
2.6 2D and 3D microtiter plate and microfluidic drug screening 
For the 2D dispersion assay, A549 MCAs ≈80 μm in diameter were 
retrieved from the microwell dish. Approximately 10–20 MCAs were seeded in 
a 96-well microtiter plate (Falcon, USA) with 10–20 per well. MCAs were 
supplemented with DMEM medium, and for a range of CI-1033 concentrations: 
1 × 10−8 M, 5 × 10−8 M, 1 × 10−7 M, 5 × 10−7 M, 1 × 10−6 M, 5 × 10−6 M, 1 × 
10−5 M, 5 × 10−5 M, and 1 × 10−4 M. For the remaining eleven drugs, 
concentrations of 5 × 10−9 M, 5 × 10−8 M, 5 × 10−7 M, 5 × 10−6 M, 5 × 10−5 M 
were used. Except for one 2D assay, drug concentration of CI-1033 recipe was 
adapted from 3D assay contained additional epidermal growth factor (EGF, 20 
ng mL−1). 
For 3D assays, collagen gel solution (200 μL, 2.5 mg mL−1, pH 7.4) was 
prepared on ice with type I collagen (123.8 μL, 4.04 mg mL−1, BD Bioscience) 
mixed with cell culture water (29.7 μL), 10× PBS (20 μL), NaOH (6.5 μL), and 
medium (20 μL) with MCAs. MCAs were supplemented with DMEM medium 
that contained an additional EGF (20 ng mL−1), and for a range of CI-1033 
concentrations: 1 × 10−10 M, 5 × 10−10 M, 1 × 10−9 M, 5 × 10−9 M, 1 × 10−8 
M, 5 × 10−8 M, 1 × 10−7 M, 5 × 10−7 M, 1 × 10−6 M, 5 × 10−6 M, 1 × 10−5 
M, 5 × 10−5 M, and 1 × 10−4 M. 
Twelve kinase inhibitors acting on different targets were used (Table 1). 
Some of these compounds are approved by the U.S. Food and Drug 
Administration (FDA) or are currently being used in clinical trials. As noted in 
Table 1, these compounds’ primarily target are either surface receptor or 
cytoplasmic kinases to inhibit specific signaling pathways. An appropriate 
range of concentrations to study was identified through an initial series of 
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experiments in the microfluidic device under 3D conditions. Drugs were mixed 
with both cancer and endothelial cell media, and applied to the endothelial cell 
channels. 
2.7 Immunofluorescent staining 
Cell culture media was removed from the devices and samples in the 
microfluidic devices were first rinsed in cold PBS and then fixed in 4% PFA 
(Sigma-Aldrich, St. Louis, MO, USA) for 15 min at room temperature. Then 
0.1% Triton-X (Sigma-Aldrich, St. Louis, MO, USA) was added and incubated 
for 5 min before blocking by Block Ace (Dainippon Pharmaceutical, Osaka, 
Japan) for 2 h. To demonstrate the endothelial cell monolayer formation, 
staining of VE-cadherin (1:100, mouse; Sigma Aldrich, USA) was carried out. 
For analysis of epithelial marker expression, E-cadherin (1:100, mouse; Sigma 
Aldrich, USA) was used to stain for cell–cell junctions; and nuclei were stained 
with DAPI (Sigma-Aldrich, USA). Fluorescent images were obtained using 
FluoView 1000 confocal microscopy (Olympus, Japan). The secondary 
antibody used was 2 mg mL-1 Alexa Fluor 488-conjugated anti-mouse IgG 
antibodies (Invitrogen, USA). For analysis of vimentin expres- sion, vimentin 
(1:200, rabbit; Invitrogen, USA) was used and incubated again with 2 mg mL-1 
Alexa Fluor 488-conjugated anti-rabbit IgG antibodies (Invitrogen, USA), and 
DNA was labeled by Hoechst (Invitrogen, USA). Fluorescent images were 
obtained using a phase-contrast microscope equipped for fluorescence (Nikon, 
Japan). 
 
2.8 Scanning electron microscopy 
Surface structures of both microwells and MCAs were investigated using 
scanning electron microscopy (SEM) (JEOL Ltd., JSM-6510LV). Prior to SEM 
imaging of the MCAs, medium was aspirated and rinsed with PBS. MCAs were 
fixed using sodium cacodylate buffer (0.1 M), paraformaldehyde (2.0%), and 
glutaraldehyde (2.5%) applied for 4 h at room temperature, then rinsed with 
sodium cacodylate buffer on a shaker table for 10 min. Post-fixation was done 
using aqueous osmium tetroxide (1.0%) in sodium cacodylate buffer in a dark 
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fume hood for 90 min, and followed by rinsing with sodium cacodylate buffer 
on a shaker table for another 10 min. Finally, samples were serially dehydrated 
by different concentrations of ethanol (37%, 67%, 95%, and 100%) on a shaker 
table for 10 min each, followed by critical point drying (Balzers, BALSERS 
CPD 030) and platinum sputtered in vacuum (JEOL Ltd., JFC-1600). 
 
2.9 ELISA and blocking experiments 
For ELISA, cell culture media from microfluidic devices were extracted after 
24 h and placed in wells of a 96-well plate with a two-fold dilution. ELISA kits 
were purchased from R&D Systems (HGF: DY294; FGF-2: DY233).  A 7-point 
standard curve was drawn for quantification of HGF and FGF, respectively. 
ELISA data expressed as absorbance at 570 nm on a microplate reader 
(Benchmark Plus).  
For blocking experiment, HGF was blocked with 20 g mL-1 anti-HGF 
(AB-294-NA, R&D Systems), FGF-2 was blocked with 5 g mL-1 anti-FGF 
(AB-233-NA, R&D Systems). The blocking antibody was added in excess to 
the experimental setup. In brief, MCAs were collected from microwells and 
blocked for 4h prior to mixing with collagen solution before injecting into the 
microfluidic device. Antibody was continuously supplied via cell media in 
microfluidic channel. Media were changed on a twice-daily basis. MCA 
dispersion was evaluated at 0 and 36h.  
 
2.10 Measurement of cancer cell nuclei dispersion 
We attempted to distinguish each cell in an MCA by identifying distinct cell 
nuclei. However, the cells in an aggregate were closely packed, making the 
segmentation difficult while MCAs remained intact. Individual cells could be 
easily identified only after the aggregate became dispersed. If there are N nuclei 
in a given aggregate, the geometric centers of nuclei are represented by , , 






Then we compute the position variation of nuclei centers from the 
aggregates center, which is given by:       
 (4) 
            (5) 
           (6) 
At last, we may determine the dispersion of a given aggregate by: 
            (7) 
In this way, we can obtain the dispersion of cells within 24 h via the 
dispersion index Δ. The ensemble of data reveals the trend of cell dispersion 
varying with time and different concentrations of drugs. Drug effects can be 
measured by the change of cell dispersion index Δ. Results are presented as 




                      (8) 
𝛥𝑖𝑛𝑖𝑡𝑖𝑎𝑙  and 𝛥𝑖  represent the dispersion index at 2 h and a subsequent 





         (9) 
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𝑁𝑖𝑛𝑖𝑡𝑖𝑎𝑙 and 𝑁𝑖 represent the cell number at 2 h and a subsequent time 
point respectively.  
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Chapter 3 Results and Discussions 
3.1 Part I: Rapid prototyping of concave microwells for the 
formation of 3D multicellular cancer aggregates1 
3.1.1 Fabrication and characterization of microwells 
The primary purpose of the first study was to develop a rapid and economical 
microwell prototyping technique for 3D MCA generation. Performance criteria 
for microwell formation are i) low-cost and suitability for cell growth, ii) 
geometrical symmetry with sufficient volume to contain the requisite number 
of cells for forming aggregates, iii) low surface roughness to prevent damage to 
the cell membrane. 
An initial series of tests using a PS untreated cell culture dish were used 
to identify parameter ranges to use for more extensive investigation (Figure 3-1). 
Two laser parameters were controlled, laser power and scanning speed, in order 
to optimize microwell formation. Results showed that the microwell was 
enlarged when laser power increased from 1 to 5 Watts at a scanning speed of 
~25 mm s-1. However, the microwell became irregular in shape when scanning 
speed exceeded ~50 mm s-1. This is because fast scanning resulted in shorter 
ablation periods per microwell, preventing the laser-generated heat from 
properly melting the substrate. By varying these two parameters simultaneously, 
it was found that multiple combinations could obtain similar results. For 
instance, the microwell created at 2 Watts and 50 mm s-1 was similar to that 
generated at 1 Watt and 25 mm s-1 in all metrics, and the same applied to other 
similar conditions. This suggests that a similar shape of microwell could be 
generated by varying the combinations of laser power and scanning speed 
conditions, with faster speeds requiring higher power to compensate for the 
shortened laser dwell time to create a hole of similar features. Because of this 
                                                 
1 The result of this section was published. Reference: Ting-Yuan Tu et al. “Rapid prototyping 
of concave microwells for the formation of 3D multicellular cancer aggregates for drug 
screening.” Advanced Healthcare Materials (2014), 3, 609-616 (Back Cover) 
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trade-off, a scanning speed of 25 mm s-1 was chosen for all the remaining 
experiments. 
 
Figure 3-1. Preliminary testing of the depth of microwells corresponding to 
power (column) and scanning speed (row) required. Testing power ranging 
from 1 Watts to 5 Watts, and scanning speed from 25 mm s-1 to 125 mm s-1 were 
instigated. Microwell structures were acquired from PDMS replica molding 
casted on PS microwells ablated by laser energy. White dotted lines are of 
separating reflection plane for clarity. 
 
After the initial series of tests was conducted to determine the proper 
laser scanning speed, conventional materials of PMMA, PDMS, and PS 
substrates were further studied and evaluated according to above criteria (Figure 
3-2). Representative side views of microwell features (Figure 3-2a) show 
significant differences in the microwell geometry from different substrate 
materials. Both PMMA and PDMS microwells yielded a more conical shape 
with increasing laser power. PS microwells, in contrast, consistently exhibited 
a curved concave shape at the bottom. In addition to the dimensions W and D, 
fabricated microwells were characterized in terms of their aspect ratio AR = 
W/D (Figure 3-2b). Results indicate that PDMS and PS microwells present 
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similar trends in both diameter and depth, resulting in comparable AR; AR = 4 
at 1 Watt and AR = 1 at ≈2–4 Watts. In contrast, PMMA shows a limited change 
in diameter but a major increment in depth, making the AR below 1 for almost 
the full range of laser power observed. 
 
 
Figure 3-2. Characterization of microwells on PMMA, PDMS, and PS. (a) 
Representative microwell features with respect to a range of laser power from 
1–5 W. For clarity, the reflection plane is indicated in white dotted line. (b) 




Isometric-view scanning electron microscopy (SEM) images were 
examined for the three materials to elucidate its surface profile in detail (Figure 
3-3). Microwell arrays demonstrated unique well geometry formed by each 
material (Figure 3-3a,d,g). PMMA microwells exhibited an irregular edge, 
debris, and micropores distributed over the entire internal surface (Figure 3-3b). 
The inner surface structure was confirmed through PDMS replica molding, 
showing elongated microwell structures with rough surfaces and high AR 
(Figure 3-3c). PDMS and PS microwells, in contrast, possessed a smooth 
surface (Figure 3-3b,e,h), and PS additionally showed axisymmetric wing 
structures residing at the edge of the microwell. The inner surface of PDMS 
revealed a cone-shaped bottom (Figure 3-3f). PS, on the other hand, displayed 
a clean and gentle concave curved bottom (Figure 3-3i). 
 
Figure 3-3. Isometric-view SEM images of microwells from three materials. A 
detailed surface profile of a single microwell is presented (middle), along with 
a negative formed by PDMS replica molding (right). (a–c) PMMA microwells 
exhibit a rough surface at the periphery and have micropores distributed over 
much of the internal surface. (d–f) PDMS microwells exhibit a smooth surface 
and a cone-shaped bottom. (g–i) PS microwells have smooth surface 
characteristics with substantial recast material around the edge and gentle 
curvature at the bottom. 
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These three materials revealed distinctive microwell geometry and 
structure after laser ablation. Pore formation on PMMA was a consequence of 
MMA monomer decomposition and expansion within the heated region (Figure 
3-3c). These volatile products formed bubbles at the surface of solidified 
PMMA (Hertzberg and Zlochower 1991), similar to what was observed in 
another ablation study (Nayak, Lam et al. 2008). The geometric difference 
between cone-shaped PDMS and concave PS microwells was mainly due to the 
different thermal diffusivity and conductivity of the materials (Figure 3-3f,i) 
(Liu and Gong 2009). Protruding structures are observed at the edge of each PS 
microwell, which can be attributed to the gradient in surface tension of PS 
caused by the temperature gradient created during the local laser heating process 
(Wu 1970). The laser beam was slightly elliptical in shape and therefore created 
an asymmetric heat-affected zone as it evaporated the PS material. The surface-
tension-driven force resulted in a slightly non-axisymmetric accumulation of 
molten liquid PS and formed a recast region after resolidification (Figure 3-3h) 
(Chen, Cahill et al. 2000). Since a majority of cells are grown in the middle of 
the concave zone, recast areas residing at the sides of PS microwells should 
rarely cause any significant effect on cell growth. The ability to observe cells 
was adversely affected in PDMS microwells due to their cone-shaped bottom 
(Figure 3-3f). PS microwells, with a gentle curvature at the bottom, were 
considered to be much more favorable for monitoring cells in real-time (Figure 
3-3i). Moreover, curved microwell structures have been reported to promote the 
formation of aggregates of more uniform size and shape (Choi, Chung et al. 
2010). 
Our findings suggest that among the three most commonly used cell 
culture materials, PS is preferred in terms of its material properties, microwell 
structure, and morphology. In addition, PS is the most commonly used material 
in tissue and cell culture research (Khan, Zhang et al. 2007; Young, Berthier et 
al. 2011), and has previously been used for thermal molding by a CO2 laser for 
various biological applications (Young, Berthier et al. 2011). The PS chosen in 
this study is from untreated cell culture dishes, which are intended for growing 
cells in stationary suspension, and are therefore both economical and readily 
available. 
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3.1.2 Generation of multicellular cancer aggregates 
A549 lung cancer cells were seeded in the 100 × 100 array of PS microwells in 
an untreated cell culture dish to test their ability for MCA formation. The 
process of cell aggregation was directly observed from day 1, the day of seeding 
cells, to day 5 (Figure 3-4a–c). On day 1, ≈20 cells were observed in each 
microwell, and the morphology and distribution of individual cells and cell 
aggregates were observed (Figure 3-4a). Due to the confinement by the 
microwell, cells formed loose cluster. From day 1 to day 4, cells were observed 
to gradually maximize adhesion with other cells to form a loose aggregate, with 
increasingly blurred cell–cell interfaces (Figure 3-4b). Compact MCA could be 
observed by day 4 or 5 (Figure 3-4c). Surface topography of MCAs at day 5 
was characterized using SEM (Figure 3-4d,e). Results showed that cells 
compactly associated with each other, forming an MCA as an integral in vivo-
like tissue. Retrieved MCAs were also stained with live cell fluorescent marker 
to test their viability. Results suggested that the MCAs remained viable after 
culturing in the microwells for 5 d (Figure 3-4f). 
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Figure 3-4. Generation and characterization of MCAs. (a–c) Cell cultures are 
shown 1, 2, and 5 d after seeding. MCAs formed within 5 d. (d) SEM image 
illustrating the location of an MCA in a PS microwell. (e) Higher magnification 
SEM image of an MCA reveals the surface properties. The majority of cells 
clumped into a compact aggregate without distinct cell–cell interface indicating 
maximized intercellular adhesion. (f) CMFDA live cell staining indicated good 
cell viability and illustrates the shape of the MCAs. (g) Size correlation between 
MCAs and different cell seeding concentrations in M1 and M2 microwells. (h) 
Probability of MCA formation across different cell seeding densities in M1 and 
M2 microwells. 
 
Our data demonstrate that PS microwells are capable of growing size-
controllable 3D MCA using an A549 lung cancer cell line. We have tested 
different cell lines in our PS microwell, for example, bladder cancer cells, breast 
cancer cells, and teratocarcinoma, revealing reliable MCA formation (data not 
shown). On an untreated surface that does not facilitate cell adhesion, cells 
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preferentially favor cell–cell adhesion and form smooth aggregates (Figure 
3-4a–c) (Liu, Abate et al. 2011). The specific morphology of the resulting 
MCAs varies with cell number, microwell dimension, and different cell lines. 
The A549 line used in this study forms MCAs (below ≈20 cells per microwell) 
that are not smoothly spherical but remain intact during subsequent 
manipulation (Figure 3-4d–f) (Desoize and Jardillier 2000; Liu, Abate et al. 
2011). 
Other factors influencing the diameter of MCAs were examined using 
the PS concave microwells of width 117 μm (M1 microwell) and 229 μm (M2 
microwell) corresponding to laser powers of 2 W and 5 W, respectively, with 
the cell seeding concentrations of 1, 5, and 10 × 104 cells per milliliter (Figure 
3-4g,h). Results showed that MCA diameter increased with increasing cell 
seeding density in M2 microwells, spanning from ≈60 μm to ≈80 μm (Figure 
3-4g); in contrast, the M1 microwells produced MCAs of diameter ≈40 μm for 
all three seeding densities. The probability of MCAs forming at different cell 
seeding concentrations was also compared (Figure 3-4h). M2 microwells 
demonstrated a consistent ≈80 to 90% probability of forming MCAs for all 
seeding densities (1, 5, and 10 × 104 cells per milliliter). For the M1 microwells, 
in contrast, the probability of MCA formation varied with seeding density. The 
microwells lacking an MCA contained either no cells or only dead cells. 
 
 
Figure 3-5. Top-view bright field micrographs of 5 by 5 M1 and M2 PS 
microwell arrays with 500 μm distance between microwells. (a) M1 microwell 
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arrays shown in black circles. Each microwell surrounds by an outer bright ring 
shape due to the reflection from recast zone. (b) M2 microwells demonstrate a 
more elliptical shape and brighter spots residing at the edge of the microwells.  
Scale bar: 200 μm 
 
The different MCA populations between M1 and M2 microwells may be 
partially explained by the different number of cells trapped in the microwell. 
Immediately after cell seeding, M1 microwells typically contained ≈5 to ≈8 cells, 
while M2 wells contained ≈10 to ≈20 cells. Another possible explanation is that 
both types of microwell were fabricated in a 100 × 100 grid with 0.5 mm spacing, 
resulting in a lower fraction of total surface covered for M1 microwells (Figure 
3-5), such that more cells would settle in the empty space between M1 wells 
without seeding in the microwells. M1 microwells were also found to have lower 
probability of forming MCAs (Figure 3-4h). This result can be explained by 
noting that M1 microwells were not only smaller in width but also in depth in a 
given AR = 1. For this reason, during medium change or when transferring the 
microwell plate from incubator to cell culture hood, more cells may have been 
disturbed and displaced from the microwell. Such a situation could be 
compensated for by using a higher cell seeding density or a more closely packed 
microwell pattern. The present findings (Figure 3-4g,h) may help to guide the 
choice of a particular size of microwell to obtain the desired size of MCA with 
sufficient frequency of its formation. For instance, to make ≈40 μm MCAs, M1 
microwells at a cell concentration of 1 × 105 cells per milliliter would be an 
appropriate choice to ensure high probability of MCA formation, while for ≈80 
μm MCAs we may choose M2 microwells with a seeding concentration of 1 × 
103 cells per milliliter. The results can serve as a reference to optimize size-
controllable MCA formation in the future. 
 
3.1.3 MCA migration assay 
To demonstrate the functionality of the formed MCAs, we chose to study two 
typical applications, cell migration, and drug screening. Cell dispersion from 
aggregates and subsequent migration play a pivotal role in a variety of 
physiological and pathological processes. The dissemination of cancer cells 
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from a solid tumor is an essential step for invasion and metastasis of tumors. 
Moreover, cells preferentially leverage different mechanisms in migrating in a 
2D or 3D environment (Meyer, Hughes-Alford et al. 2012). Therefore, 
functional studies of cancer cell migration could potentially assist in the 
understanding of such invasion process. To explore this, we studied cell 
migration both on a 2D substrate and in a collagen-based ECM 3D environment.  
In the 2D migration assay, A549 MCAs were seeded on a polystyrene 
cell culture substrate and imaged from 2–24 h (Figure 3-6a). Migration was 
initiated by cells attached to the substrate, defined as a “precursor film” 
(Douezan, Guevorkian et al. 2011). Tracking the motion of each cell revealed 
that the MCAs consistently spread in a radial fashion (Figure 3-6b). During the 
process of A549 MCA spreading, the precursor film maintained cell–cell 
contact and migrated collectively for 8–10 h. Large filopodia were observed at 
the front film edge (Figure 3-6c). Collective migration was gradually 
superseded by individual cell mobility as cells began to escape from the outer 
edge (Figure 3-6d). 
 
 
Figure 3-6. Illustration on MCA migration in 2D and 3D conditions using 
microtiter plate over 24 h. (a) Schematics of MCAs placing on 2D surface. 
MCAs were put in contact directly with microtiter 96-well substrate. Each well 
contains ≈10-20 MCAs randomly distal from one another. Dispersion was 
initiated from the contact surface between MACs and substrate. (b) Time-lapse 
tracking of MCA dispersing in 2D. Single cells were tracked over 24 h, 
displaying consistent outward directional migration. (c) Phase-contrast image 
of an MCA spreading in 2D for 8 h while the MCA maintained cell-cell contact. 
(d) The same MCA dispersing for 24 h in 2D. Cell movement translated from 
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collective cell migration to single cell migration. (e) Schematics of MCAs 
embedding in 3D native type I collage. The microtiter plate was placed upside-
down during gel cross-linking to ensure MCAs suspended in 3D.  (f) Time-lapse 
tracking of MCA dispersing under 3D condition. (g) Phase-contrast image of 
early invasion of an MCA dispersing in 3D collagen. Early invasion was 
observed through formation of pseudopodia at 2 h, indicated by arrows. (h) The 
same MCA broke up after 24 h, and a single escaped cell was observed 
(indicated by the arrow).  
 
Previous work has shown that the cell aggregate spreading on a 2D 
planar substrate can be described as a competition of cell–cell and cell–substrate 
adhesion (Ryan, Foty et al. 2001). Douezan et al. further demonstrated that the 
aggregate spreading process resembles a liquid–gas transition that depends on 
the cohesiveness of the aggregate. To examine the kinetics of evolution of the 
monolayer, we pursued an analytical approach similar to that described by 
Douezan et al. (Douezan, Guevorkian et al. 2011) to quantify MCA spreading 
on a planar substrate by measuring spreading area while cells migrated in the 
collective mode during the first 10 h (Figure 3-7). In brief, the dynamic process 
of aggregate spreading can be modeled as a function of adhesive energy gain 
per unit time and viscous dissipation of the precursor film slipping on the 
substrate. The governing equation of the spreading film is the balance between 
the surface energy gain and the viscous dissipation, and can be described as: 
 𝑅2 (ln (
𝑅
𝑅1
) − 1) + 𝑅1
2 = 𝐷𝑡,               (10) 
where R is the radius of the precursor films, R1 is the radius of the initial contact 
line, t is time, and D is the diffusion coefficient of the precursor film which is 
the layer of MCA spreading on substrate. It is observed that spreading area of 
the precursor film at each time point is proportional to the initial size of the 
MCA, in that larger aggregates spread faster than smaller ones (Figure 3-7a). 
We also examined the influence of epidermal growth factor (EGF) addition on 
the precursor film. As expected, results exhibit faster migration with added EGF 
independent of aggregate size (Figure 3-7b). These results further support that 
this transition occurs consistently with varied MCA size but varies with 
cohesion strength (Figure 3-7). One explanation for this result is that MCA 
cohesiveness was altered due to the addition of EGF. EGF is known to promote 
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E-cadherin endocytosis (Lu, Ghosh et al. 2003), as well as to repress E-cadherin 
transcription in a short time (Lee, Chou et al. 2008). The loss of E-cadherin 
resulted in reduction of cell–cell adhesion energy, which preferentially caused 
aggregates to dissociate. 
Experimental data were fitted (Equation 10) and the two conditions (no 
EGF or 20 ng EGF) fell on two distinct curves (Figure 3-7b). The slope of the 
two lines depicts the value D, where higher D represents weaker cell-cell 
adhesive energy in aggregates. Our results showed a slight power-law instead 
of linear energy dissipation. There are several factors that may affect these 
results. First, our A549 cell line revealed pronounced lamellipodia formation by 
the front cells of precursor films, causing an increased spreading area over time 
as lamellipodia formation increased. This may contribute to cell-substrate 
adhesion increasingly over time, helping to explain the non-linear response 
curve (Figure 3-7). In contrast, the murine sarcoma (S-180) cells for which 
Douezan proposed equation 10 remain relatively consistent in size when 
migrating on a 2D substrate during spreading. Second, equation 10 models 
competition between cell-cell and cell-substrate interaction, where the substrate 
is coated with fibronectin. In our case, fibronectin coating was not applied to 
the surface, which may decrease initial cell-substrate adhesion.  
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Figure 3-7. Spreading of precursor films of MCAs on a 2D plane substrate. (a) 
Spreading area of precursor films with different sizes of MCAs. Blue: without 
EGF; red: 20ng EGF-added. The area of spreading is correlated with the size of 
MCAs. (b) Evolution of precursor films with time. The dissipation energy is 
sought to be relevant to the cell-cell intracellular adhesion energy. EGF addition 
triggered MCAs to become dispersal compared to the control. 
 
In addition to the 2D assay, migration in 3D was observed by embedding 
A549 MCAs in native type I collagen (Figure 3-6e). Migration in 3D was 
confirmed by observing their trajectories and morphologies over 24 h (Figure 
3-6f). In the first 2–4 h, some protrusions extended into the gel matrix (indicated 
with arrows) to present at the surface of the MCA (Figure 3-6g). After 4 h, cells 
in the aggregate started to move, subsequently causing a rearrangement in MCA 






outwards. These pseudopodia- or invadopodia-like protrusions from the MCAs 
are actin-rich structures important in cancer cell migration and invasion. 
(Shankar, Messenberg et al. 2010) In most cases, the MCA then broke into two 
or three multicellular pieces, and individual cells also began to escape from the 
aggregate (Figure 3-6h), showing that cells depend on different mechanisms 
when migrating in the matrix (Li, Ota et al. 2008; Sabeh, Shimizu-Hirota et al. 
2009). 
 
3.1.4 Summary of Part I 
Despite the many advantages of our present approach, some limitations 
should be addressed: i) The size of the microwell is confined to ≈100–400 μm 
due to the laser beam size. ii) Thermal processing created a recast zone that 
resides on the surface area and reduces the number of PS microwells that can 
be created on a given surface area. iii) MCAs must be retrieved manually, a 
problem common to other microwell methods. The PS microwell dish presented 
is manufactured directly by patterning with a desktop CO2 laser, requiring no 
additional fabrication processes. Drilling a microwell requires less than 500 ms, 
and a pattern of 1000 microwells can be generated in 2.5 min. Our approach of 
manufacturing a microwell array from a Petri dish facilitates liquid handling 
and ensures ease of material access suitable for most biological and medical 
laboratories. The PS dishes that we used in this study could be reused as many 
as five to seven times. This microwell technique can potentially be integrated 
with a microfluidic system. Using this approach, medium and reagent could be 
exchanged rapidly and conveniently. Potential drug screening assays may be 
performed within the microfluidic setup, eliminating the need to retrieve 
aggregates from the wells. The small channel volume of microfluidic devices 
could allow minimal consumption of expensive compounds. With proper design 
of fluidic compartments, individual environment conditions could be created 
for each MCA in a microwell to attain high-throughout screening. 
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3.2 Part II: Screening of migration-inhibition drugs in 2D and 3D 
environments2 
3.2.1 Conventional microtiter plate assays 
The primary purpose of this study was to examine the importance of a 3D 
microenvironment and co-culture with an endothelial monolayer in the 
screening of potential drug targets to inhibit cell dispersion.  In numerous other 
biological processes, the nature of the local physical environment and signaling 
from neighboring cell types would lead to significant differences in cellular 
responses. Studies have also demonstrated that MCAs showed dramatically 
different responses to drug treatment in 2D and 3D environments (Desoize and 
Jardillier 2000; Kloss, Fischer et al. 2008).  
As a proof of concept that cell migration can be affected according to 
drug treatment, we treated MCAs with EGF and tested the inhibitory activity of 
EGFR tyrosine kinase antagonist (in Materials and Methods). CI-1033, a pan-
ErbB tyrosine kinase inhibitor, has been reported in a number of Phase I and 
Phase II clinical trials in patients with non-small cell lung cancer (Janne, von 
Pawel et al. 2007; Zinner, Nemunaitis et al. 2007). The influence of CI-1033 on 
MCA dispersion was investigated under the two conditions, MCA migrated in 
contact with 2D substrate or in 3D collagen matrix (Figure 3-6). Using as a 
baseline for comparison the condition where only EGF was applied, the change 
of cell dispersion index Δ (see Equation 7), a measure of the size of the region 
of cell spreading, was used as an indicator of the effectiveness of the drug. For 
different drug concentrations applied in the two conditions, normalized 
dispersion (Equation 8) was plotted against time (Figure 3-8). 
Both 2D and 3D dispersion increased with time except in cases of 
complete inhibition of dispersion for high doses of CI-1033. The growth rate of 
cell dispersion is inversely correlated to the dimensionality of the environment 
                                                 
2 The result of this section was published, with my contributions relevant to this thesis were 
covered. Reference: Amir R Aref et al “Screening Therapeutic EMT Blocking Agents in a 
Three-Dimensional Microenvironment.” Integrative Biology (2013), 5(2), 381–389. 
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and the dose of CI-1033. Cells in 2D migrated more than cells in 3D at all 
concentrations of drug (Figure 3-8a). Also, full inhibition of cell migration in 
2D conditions required a ≈50 μM dose of CI-1033, two orders of magnitude 
higher than the dose of ≈500 nM needed to inhibit migration in 3D (Figure 3-8b). 
Data at the 24 h endpoint are plotted against the dosage to obtain a dose-
response curve (Figure 3-9), and to determine the effective dose of CI-1033 for 
dispersion inhibition. Curve fitting results revealed that the IC50 value dropped 
from 3 μM in 2D to 30 nM in 3D.  
 
Figure 3-8. Screening of EGFR inhibitor onA549 MCA in 2D and 3D 
conditions using microtiter 96-well plate. Representative time-lapse intervals 
show MCA dispersion across different concentrations of drugs CI-1033 at 2, 8, 
16, and 24 h. Presentation of both (a) 2D conditions and (b) 3D conditions were 
scaled to the same range. Both the highest and the lowest dosages for 2D 
conditions are 1 order of magnitude larger than that of 3D conditions. 
The 2D dispersion assay relies on different mechanisms for cell 
migration and differs considerably from the 3D assay in terms of A549 MCA 
response. As a result of a competition between cell–cell and cell–substrate 
adhesion, MCA 2D migration was more strongly affected by MCA size and 
choice of substrate. These factors showed less effect on MCAs encapsulated by 
ECM in the 3D assay, where matrix metalloproteinases (MMPs) for ECM 
remodeling are known to be an important factor in addition to the strength of 
adhesion and cohesion. Our data show that compared to a 2D environment, the 
concentration required for inhibition of cell dispersion, as reflected by the IC50, 
fell by a factor of nearly 100 in 3D conditions (Figure 3-9). In contrast, in a 
different experimental setup studying cytotoxic drug resistance, A549 MCAs 
showed a 10 to 100-fold change in resistance compared with that of 
monoculture (Desoize and Jardillier 2000). 
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Although these results underscore the importance of different assay 
types for MCAs in light of future drug screening applications, in vitro assays 
used to screen for anti-metastatic compounds should replicate the local tumor 
microenvironment to the extent possible. For instance, inclusive of a 
microvasculature, growth factors and ECM could better mimic the mechanisms 
driving tumor progression.   
 
Figure 3-9. Dose-response assays on A549 MCAs. Both 2D and 3D dispersion 
were performed utilizing A549 MCA in the microtiter plate setup. Drug effect 
of CI-1033 was evaluated after 24 h. 
 
3.2.2 Microfluidic assays 
As a step toward replicating in vivo conditions, we developed a tumor 
microenvironment model recapitulating physical and biochemical contexts 
suitable for drug screening applications, in which A549 MCAs were suspended 
in the gel region of the microfluidic system (Figure 2-2) in the absence or 
presence of an endothelial cell monolayer.  
In order to understand the co-culture effect from HUVECs, a first series 
of experiments was conducted to determine the potential invasion-inducing 
activity of the endothelial cell culture medium. Results demonstrated that A549 
MCAs do not dissociate within a 36 h period of incubation in the presence of 
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the endothelial cell culture medium alone (Figure 3-10A) even though it 
contains basic fibroblast growth factor (FGF-2), EGF, and recombinant-3 
insulin-like growth factor-1 (R3-IGF1) and fetal bovine serum (FBS). MCAs 
do dissociate, however, in the presence of endothelial cells within 12 h (Figure 
3-10B) whereas dissociation is fully suppressed under co-culture conditions 
using the EGFR inhibitor CI-1033 at 300 nM concentration (Figure 3-10C).  
 
Figure 3-10. 3D fluorescent images of the co-culture microfluidic drug 
screening assays. Time-series of each A549 MCA dispersion in the collagen 
matrix was captured at 0 h, 12 h and 36 h. (a) A549 MCA monoculture in 3D 
collagen without HUVECs monolayer over three timepoints. MCA remained 
intact throughout 36 h, where triangles depicting the PDMS pillars on the edge 
of collagen. (b) Co-culture of HUVEC monolayer and A549 MCA in the 
microfluidic device. A549 gradually dispersed over the course of 36 h. (c) CI-
1033 addition to the co-culture microfluidic in the presence of the HUVECs. 
Adding EGFR inhibitor reversed MCA dispersion induced by HUVECs. Red: 
nuclei of A549 cells; green: HUVEC. 
 
To gain further understanding of this drug inhibitory effect, twelve drugs 
interfering with EGFR, IGFR, PDGFR and TGF-βRI/ ALK5-dependent 
activation as well as others acting upon intracellular kinases such as Src, MEK 
and Akt were tested. An appropriate range of concentrations to study was 
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identified through an initial series of experiments in the microfluidic device 
under 3D conditions. Drugs were mixed with both cancer and endothelial cell 
media, and applied to the endothelial cell channels. Each drug for at least two 
concentrations along with one control (dose = 0; n = 12 devices) was tested 
(Figure 3-11) in order to determine concentrations needed to produce full 
inhibition of dispersion in a 36 h period of incubation (Table 1). Parallel 2D 
screening experiments were performed using conventional microtiter plate 
described in previous section, and the results, expressed in terms of the 
corresponding IC50 values, were determined. In every case but one, the IC50 
dose was considerably higher even than the dose required for full inhibition in 
3D (Table 1).  
Furthermore, our data in 3D co-culture are in closer agreement with 
plasma concentrations for CI-1033 reported to be effective in clinical trials 
(≈102 nM) (Calvo, Tolcher et al. 2004; Simon, Garrett et al. 2006). Similar 
results were found with the remaining eleven drugs. Interestingly, when the 
MCAs are fully suspended in gel without an endothelial monolayer, they remain 
intact without spreading during the entire 36 h observation period, even in the 
absence of drug and in the presence of endothelial cell growth medium. 
These results are consistent with the previous findings using microtiter 
plate, demonstrating both qualitative and quantitative differences in 2D and 3D 
screenings, and further differences depending on whether or not the tumor cells 
communicate with a nearby endothelial monolayer. The 2D dispersion assay 
differs considerably from the 3D assay in terms of the MCA response. For 
example, in the case of CI-1033, an EGFR inhibitor, the IC50 for inhibition of 
cell dispersion fell by nearly a factor of 100 comparing 2D to 3D dispersion and 
10 (Figure 3-9) to 3D microfluidic co-culture (Figure 3-10 and Table 1). In 
another case of A83-01, a TGF-βR inhibitor, the differences in effective dose 
between 2D dispersion and 3D culture in the microfluidic system and in 
combination with endothelial cells were considerable, more than three orders of 
magnitude (5 nM vs. 5 μM). Concentrations of the 12 drugs found to be 
effective in inhibiting MCA dissemination all fall in the range of 2 μM or less, 
suggesting that any of these could be potential candidates for therapy. 
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Rapid dissociation of the compact A549 MCAs when in communication 
with the endothelial monolayer can be reversed by inhibitors of EGFR and TGF-
βR, suggesting that endothelial cells produce EGF (Tunica, Yin et al. 2009) and 
TGF-β (Hannan, Kourembanas et al. 1988) family members. Previous works 
showed A549 may activate pathways mediated by EGFR (Jaramillo, Banville 
et al. 2008) and TGF-βR1 (Kasai, Allen et al. 2005; Kim, Jang et al. 2007) to 
induce a more invasive phenotype.  It should be noted that the MCA 
dissemination may act in a concentration-dependent manner via dispersal 
factors in the media or paracrine signaling. In the case of microtiter 3D assays, 
dispersion was also achieved upon addition of 20 ng mL-1 EGF in the absence 
of the endothelium. Monoculture of MCA, however, does not dissociate despite 
its autocrine loop and endothelial media contained EGF, which may explain 
why it failed to achieve threshold of receptor activation. Both 3D screening in 
conventional well-plate and microfluidic device revealed similar effective dose 
near 300 nM by inhibiting EGFR using CI-1033. Other EGFR inhibitors, BMS-
599626 and Gefitinib, also proved effective at similar concentration, suggesting 
a possible saturation effect in both receptor activation and inhibition on EGFR 
signaling involved to prevent dispersion.  
 
Table 1. Inhibitors list summarizing the targets and doses in 2D microtiter plate, 
at 24 h and in 3D microfluidic platform at 36 h. Effective dose represents the 
concentration required to fully inhibited the MCA dispersion in the microfluidic 
co-culture platform. Media used for 2D screening was DMEM supplemented 
with 10% FBS. In 3D, the mixture of DMEM and HUVEC growth media was 
applied in the presence of HUVECs. 
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Figure 3-11. Quantitative analysis of drug screening on MCA dispersion and 
proliferation in the microfluidic device in the presence of HUVECs at 36 h. (a) 
Normalized dispersion for twelve inhibitors and one control. (b) Representative 
normalized dispersion performed utilizing AZD-0530, a Src inhibitor, with 
three concentrations over three timepoints, at 0 h, 12h and 36 h. (c) Normalized 
proliferation for twelve inhibitors and one control. (d) Representative 
normalized proliferation performed utilizing AZD-0530 with three 
concentrations over three timepoints, at 0 h, 12h and 36 h. The concentration of 
each drug was optimized to discern MCA inhibition. The effective 
concentrations for full inhibition for twelve inhibitors are summarized in Table 
1. 
 
Normalized cell proliferation (NN, Equation 9) was used to evaluate cell 
growth and normalized cell dispersion (ND, Equation 8) was used to evaluate 
cell migration away from the MCA in the presence of drugs. Time-dependent 
cell proliferation and dispersion (Figure 3-11A and C) indicated that the control 
condition exhibited the strongest cancer cell activity in terms of both 
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proliferation and dispersion. Compared with the control condition, increasing 
drug dose caused a significant (p < 0.05) decrease in cell proliferation as well 
as a reduction in cell dispersion (Figure 3-11B and D). 
By plotting normalized proliferation against normalized dispersion of 
cancer MCAs at 36 h (Figure 3-12), we are able to define four quadrants to 
characterize the dose response for each drug. The upper right quadrant where 
the control data points fall indicates cases with high rates of proliferation and 
dispersion. Most drug-treated data lie in the lower left quadrant corresponding 
to low proliferation and low dispersion activity. Therefore, it appears that for 
the conditions tested, whenever the drug was effective in reducing cell 
dispersion, it also inhibited proliferation. At the higher doses, the effects on 
proliferation were more marked. 
 
Figure 3-12. Normalized cell dispersion and corresponding cell number at 36 h. 
Four quadrants were defined to characterize the dose response for each drug. 
The upper right quadrant indicates cases with high rates of proliferation and 
dispersion, where we find the control conditions. Most drug-treated data lie in 
the lower left quadrant with low proliferation and low dispersion activity. 
Therefore, it appears that for the conditions tested, drugs reduced cell dispersion 
and cell proliferation simultaneously. 
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3.2.3 Evaluation of EMT phenotype and growth of endothelial cells  
Since EMT has been implicated crucial in the early metastatic process, 
identifying this transitional phenotype may provide a basis for understanding 
progression of carcinoma towards dedifferentiated and more malignant states 
(Thiery 2002). Multiple signaling pathways have been associated with EMT of 
carcinoma cells including activation of tyrosine kinase surface receptors such 
as EGFR, TGF-βR1 and hepatocyte growth factor receptor (HGFR/c-Met). 
Numerous cytokines, extracellular matrix components and MMP also play a 
major role in EMT (Page-McCaw, Ewald et al. 2007; Joyce and Pollard 2009; 
Thiery, Acloque et al. 2009; Hanahan and Weinberg 2011). Some of these 
pathways may act in concert through reciprocal interaction between stromal and 
carcinoma cells to induce EMT. (Scheel, Eaton et al. 2011)  
In conventional 2D culture, it is well-established that A549 can undergo 
extensive conversion to a mesenchymal-like morphology in response to EGF 
and with TGF-β (Kasai, Allen et al. 2005; Kim, Jang et al. 2007). We used 
confocal immunofluorescence microscopy to exam two EMT markers i.e. 
vimentin and E-cadherin.  The results showed increment of vimentin and loss 
of E-cadherin from the MCAs after co-culturing with HUVECs for 36 h (Figure 
3-13), suggesting this conversion could be manifested in the context of MCAs 
disseminating from 3D collagen scaffold in the presence of HUVECs. Since 
several pathways can be activated by endothelial-derived growth factors, drugs 
could be designed that inhibit the kinases involved in activation of A549 cells 
towards metastasis.  
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Figure 3-13. Immunostaining of EMT markers on A549 MCAs at 0 h and 36 h 
in co-culture with HUVECs in the microfluidic platform. (a-b) Expression of 
vimentin in MCAs at 0 h. MCA was intact with little expression of vimentin. 
(c-d) Expression of vimentin in MCAs at 36 h. MCA was dispersed with high 
expression of vimentin at 36 h. Blue: nuclei; green: vimentin. (e–h) High 
expression of E-cadherin in MCAs was at 0 h. After co-culture with HUVECs 
for 36 h, the MCA dispersed and expression of E-cadherin disappeared. Blue: 
nuclei; green: E-cadherin. 
 
Evaluation of drug effects on HUVEC monolayer growth was 
performed based on the ratio of cell number at 36 h to that at 0 h (Figure 3-14a,b). 
Representative fluorescence images showed the HUVEC monolayers in the 
presence of drug LY 364947 at 0 h and 36 h, respectively. HUVECs were 
observed to migrate into collagen matrix, and morphology was observed to vary 
upon different drug treatment. In general, normalized cell number was found to 
be near 1 to 1.5 fold, demonstrating the growth of HUVECs was maintained at 
similar levels under each condition (Figure 3-14c).  
It should be noted that the semi-confluent HUVEC monolayer may be 
improved with longer incubation time during initial seeding. On one hand, 
owing to the MCA seeding was done prior to HUVEC seeding, the incubation 
time for HUVEC to attach could not exceed 2 h without adding the drugs, 
otherwise the MCA may begin to dissociate.  On the other hand, although 
adding drugs in due time could prevent MCA dispersion, this might have an 
adverse effect on the HUVEC monolayer before it became fully established. 
Therefore, modification of device, as described in the next section, may provide 




Figure 3-14. Evaluation of drug effects on HUVEC monolayer growth. (a) and 
(b) Representative fluorescence images of HUVEC monolayers in the presence 
of drug LY 364947 at 0 h and 36 h, respectively. (c) Plots of normalized 
HUVEC cell number for each compound at the highest dose used in this study. 
Normalized cell number is the ratio of cell number at 36 h to that at 0 h. 
 
3.2.4 Summary of Part II 
Cell migration utilizes different mechanisms depending on whether the 
migration is on a 2D substrate or through a 3D matrix (Decaestecker, Debeir et 
al. 2007; Meyer, Hughes-Alford et al. 2012). MCA migration on 2D substrates 
was earlier described as a competition of force balances between cell–cell and 
cell–substrate (Figure 3-7). Therefore, different substrates and different size 
MCAs would play a major role in determining the tendency of the MCA to 
disperse. In 3D environments, however, the MCA is encapsulated by the matrix, 
where migration is not only influenced by the balance of forces, but also by the 
secretion of MMP needed for ECM degradation and remodeling. EMT, in part, 
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is known to promote MMP secretion. Indeed, a recent study (Meyer, Hughes-
Alford et al. 2012) has demonstrated that there is little overlap between the 
signaling pathways used in 2D and 3D migration. In addition, cell–cell signaling 
plays a critical role, as demonstrated here between the HUVEC monolayer and 
the tumor cells, and this signaling also likely to differ between the 2D and 3D 
conditions. Therefore, our results suggest the importance of more realistic in 
vitro screening methods in identifying drugs that might inhibit cell dispersion 
in vivo. A change in the local environment, whether the cells are embedded in 
collagen gel or in contact with a rigid surface, can significantly alter the 
concentration of drug needed to inhibit the MCA dispersal response. 
Another objective of these studies was to demonstrate the feasibility of 
using a 3D microfluidic co-culture system as a screening platform for drugs 
aimed at preventing tumor dissemination. The 3D MCA system in this 
microfluidic design offers a unique opportunity to screen drugs for their ability 
to interfere with invasion into adjacent matrix. The optically transparent 
microfluidic system not only reproduced the ECM and multi-type cell 
microenvironment essential for a tumor to develop in vivo, but also provided a 
means for quantitative, automatic detection of cells and measurement of indices 
reflecting invasive progression in a time-dependent manner. 
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3.3 Part III: Drug combinations and dispersal factors from 
endothelial cells instrumental in preventing carcinoma 
dissemination3 
3.3.1 Validation of a modified microfluidic system based on the one-gel 
device 
With the co-culture microfluidic system being built to recapitulate tumor 
microenvironment in vitro, the primary purpose of this section is to leverage 
similar microfluidic screening concept to investigate drugs as a single agent or 
in combinations, as well as to identify the dispersal factors from the secretions 
of HUVECs, to prevent carcinoma dissemination.   
For this study, a microfluidic system (Figure 2-3) was used, similar in 
design to the previous-section reported system, except that it incorporated two 
different 3D collagen compartments between the two media channels. In the 
previous design, MCAs embedded in the gel was seeded first and followed by 
endothelial cell seeding. This modification allows the revision of the cell-
seeding order in the microfluidic channels. Collagen was seeded to 1st gel 
channel and heat polymerized. Then, this first 1st gel could separate media 
channel and 2nd gel channel allowing liquid infusion in each channel 
compartment. Endothelial cells seeded to the media channel, therefore, could 
grow with ample time prior to MCA seeding to the distal 2nd gel channel. 
Experimentally, the growth of endothelial monolayer structure to establish 
sheet-like attachment and exhibit clear cell-cell junctions took 4 – 6 h depending 
on cell seeding and passage, as evidenced by VE-cadherin staining (Figure 
2-3d). Further growth of the monolayer to fully cover the side of collagen matrix 
to the top of the PDMS surface required minimum 36 h. Staining of junctional 
protein VE-cadherin at 36 h (Figure 2-3d) demonstrated an intact monolayer 
structure covering the collagen gel assemble to mimic the vascular well.  
                                                 
3 The result of this section is under preparation for a manuscript. Reference: Jing Bai and Ting-
Yuan Tu et al. “Identification of drugs as single agent or in combinations to prevent carcinoma 
dissemination in a microfluidic 3D environment.” Oncotarget (2015) 
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This modification of the microfluidic was designed in an attempt to 
resolve issues found in previous design: balance between endothelial cell 
growth (Figure 3-14) and MCA dissemination. Previously, endothelial cells 
were grown 1 – 2 h prior to drug addition, in which the given time allowed only 
semi-confluent cell attachment. Adding drugs may thus affect subsequent 
growth of endothelial cells. However, if the endothelial cells were given 
sufficient time to grow, MCAs may have already initiated cell migration for 
dispersion. Therefore, the new design could deal with a better control of the 
growth of endothelial cells to fine-tune the time needed prior to MCA seeding 
according to its condition and passage for each experiment. Growth of 
endothelial monolayer for 36 h provided a stabilized, low permeability 
monolayer, which was tested by applying 70kDa dextran rhodamine (Figure 
2-3e). A significant drop of fluorescence intensity at the boundary of the 1st gel 
(Figure 2-3e) where the HUVEC monolayer resides indicated an intact, low 
permeability monolayer. This model could be key in reproducing the dynamics 
of drug diffusion and the process of drug diffusion across the blood/lymph 
vessel wall into the extracellular matrix surrounding the tumor for future studies. 
To validate the drug screening capability of the modified microfluidic 
system, A549 MCAs were used. The results demonstrated that MCAs do not 
disperse when cultured in the absence of HUVECs. In the presence of HUVECs, 
aggregates do disperse, but each of MK-2206, AZD-0530, A83-01 and CI-1033 
were able to fully suppress the dispersion, each at a particular dose within the 
range of concentrations tested (Figure 3-15b). Synergistic effects were then 
investigated between each pair of drugs. Interestingly, the EGFR inhibitor, CI-
1033 and an AKT inhibitor showed a significant synergistic effect in that the 
amount of drug required for inhibition of dispersion was reduced to one-fifth 
the level required for each drug individually. The drug concentration needed for 
full inhibition of aggregate dispersion was reduced from 500 nM to less than 
100 nM for each (Figure 3-15c). 
Rapid dissociation of the compact A549 MCAs induced by endothelial 
cells could be reversed by inhibitors of several Receptor Tyrosine Kinases 
(RTKs) and intracellular kinases (Figure 4), as shown previously (Table 1). 
Present results with the new system proved to be consistent with previous 
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inhibition data in that similar concentrations were required for full inhibition, 
validating the revised microfluidic design. It is also remarkable that a 
synergistic effect was observed using an EGFR inhibitor (CI-1033) in 
conjunction with an Akt inhibitor (MK-2206). Previous study has suggested that 
this can be attributed to a synergistic effect which leads to actin cytoskeletal 
disorganization, and potentially regulated by targeting rho proteins (Heyder, 
Gloria-Maercker et al. 2005; Zhao, Le Francois et al. 2010). These findings 




Figure 3-15. Screening therapeutic drugs on A549 aggregates over 36h. (a) 
Staining of EMT markers E-cadherin and vimentin in A549 aggregates at 0h 
and 36h. Green: E-cadherin/vimentin; blue: DAPI-stained nuclei. (b) 
Normalized dispersion and cell number measured for three concentrations with 
four drugs (MK-2206: Akt inhibitor; AZD-0530: Src inhibitor; A83-01: TGF-
βR inhibitor; CI-1033: EGFR inhibitor). (c) Normalized dispersion measured 
over time for analysis synergistic effects between CI-1033 and MK-2206, at 
four different concentrations. 
 




























































































































3.3.2 Identification of drug combinations for T24 bladder carcinoma   
In our next studies, we sought to determine a drug combination that might be 
effective in preventing the dispersion of an even more highly invasive tumor 
cell, the T24 bladder cancer cell line. Dosage dependent drug screening was 
demonstrated on T24 MCAs in the microfluidic device in the absence and 
presence of HUVECS.  In contrast to A549, T24 MCAs revealed spontaneous 
dispersion in the absence of HUVECs (Figure 3-16a). This spontaneous 
dispersion could not be suppressed by any of the four drugs individually, except 
that partial inhibition was observed in the Src inhibitor AZD-0530 treated group 
at 10µM (Figure 3-16b), the highest concentration set to prevent unwanted 
cytotoxic effect. Results indicated that, among the four drugs tested, AZD-0530 
was the most effective in preventing spontaneous dispersion of the T24 
aggregates. In the presence of HUVECs, each drug showed some inhibitory 
activity on MCA dissociation with increasing inhibitor concentration albeit not 
reducing the dispersion value below 3 (complete inhibition corresponds to a 
value approaching 1) individually. Even AZD-0530 was unable to inhibit 
dispersion when MCAs were co-cultured with HUVEC (Figure 3-16c). 
In general, the T24 bladder carcinoma cell line exhibited a more 
aggressive behavior than lung adenocarcinoma A549. In T24 cells, spontaneous 
dispersion could readily be observed in 3D collagen gels. In both of presence or 
absence of endothelial cells, the concentration required for inhibition for T24 
MCA were around 10 fold higher than A549. Drugs targeting Akt, EGFR, or 
TGFβR suppressed the T24 MCA dispersion from a 6 – 7 fold to 3 fold, increase, 
suggesting that endothelial cells produce EGF, TGFβ family members as 
previously reported. The partial inhibition of AZD-0530 in the absence of 
HUVEC indicated that dispersal factors secreted by endothelial cells could 
mediate T24 to become more invasive while Src is inhibited (Figure 3-16d,e).  
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Figure 3-16. Screening therapeutic drugs on T24 aggregates over 36h in the 
presence/absence of HUVECs. (a) Staining of EMT markers E-cadherin and 
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DAPI-stained nuclei. (b) Normalized dispersion of T24 cells with four drugs, in 
the absence of HUVECs. (c) Normalized dispersion of T24 cells with four drugs, 
in the presence of HUVECs. (d) Comparison of normalized dispersion between 
control and AZD-0530 treated group, in the presence/absence of HUVECs. (e) 
Qualitative images of the four groups at 0h and 36h, respectively. 
 
In a search for drug synergy that could prevent T24 MCA dispersion, 
different combinations of drugs with varying concentrations (Figure 3-17) were 
tested in the presence of HUVECs. Although all results showed significant 
reduction of dispersion to ~half that of control, dispersion among different 
combinations was insignificant. In addition, MCAs were still dispersed in all 
conditions. Only when the 4 drugs were added in combination at a 10 µM 
concentration (Figure 3-18a,b), was almost complete inhibition obtained, which 
could be considered an additive rather than synergistic effect. 
It is worthwhile noting that the spontaneous dispersion of T24 
aggregates alone, without co-culture, is about 3, similar to the value observed 
in co-culture with HUVECs when maximally inhibited by individual drugs. 
Even when used in combination, full inhibition of T24 cancer aggregates could 
not be achieved with the combination of any two drugs (Figure 3-17) 
Furthermore, when all four drugs were used in combination at 10µM each, 
complete inhibition was still not observed (Figure 3-18a,b), albeit a slight 
improvement (dispersion was reduced to 1.5-2) was observed compared to any 





Figure 3-17. T24 cellular response to drug synergistic doses. Normalized 
dispersion measured over time for synergistic effect analysis of four drugs, with 
every two drugs in combination. All results showed significant deduction of 
dispersion to half compared to control. However, dispersion was still observed 
and inhibition among different combinations was insignificant.  
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Figure 3-18. Drug combination analysis on T24 cell aggregates. (a) Qualitative 
images showing the effect of drug used in combinations of four, in the presence 
or absence of HUVECs at various doses. (b) Comparison between AZD-0530 
and drugs in combinations of four, in the presence or absence of HUVECs at 
various doses.  Concentrations given are for each drug individually (e.g. 
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3.3.3 Identification of growth factors secreted from HUVEC inducing 
T24 dispersion 
Given that T24 MCAs showed partial inhibition of AZD-0530 during 
monoculture, while dispersion was restored in the presence of HUVEC, we 
suspected that there might be some factor(s) other than those targeted by one of 
the drugs listed secreted by HUVECs that induce dispersion. To investigate the 
role of paracrine signaling by HUVECs to T24 cells, individual growth factors 
were examined in the absence of HUVECs and in the presence of AZD-0530. 
A group of growth factors, including TGF-β1, TGF-β3, EGF, FGF-2, HGF and 
PDGF, was selected in simulating possible secreted factors by endothelial cells 
to mediate dispersal conversion.  
In the presence of AZD-0530, HGF and FGF-2 MCA dispersion was 
reduced to a level comparable to that obtained in co-culture with HUVECs, 
whereas TGF-β3 and EGF exhibited less of an effect (Figure 3-19). To analyze 
whether endothelial cells might be inducing EMT in T24 cells through secretion 
of HGF/FGF-2, we first measured HGF/FGF-2 secretion by HUVECs using 
ELISA. Concentrations of FGF-2 in co-culture were found to be three times 
higher than in cultures with aggregates only (Figure 3-20a). Similarly, 
endothelial cell secretion lead to 5 fold higher concentrations of HGF in the co-
culture condition compared to MCA alone (Figure 3-20b). The presence of 
AZD-0530 does not affect the concentrations of either growth factor, and adding 
endothelial growth media – EGM to the MCAs has no significant effect. This 
suggests that endothelial cells can produce HGF and FGF-2 even without co-
culture with T24 aggregates while in co-culture conditions an increased 




Figure 3-19. Representative images of MCA dispersion induced by growth 
factors in the presence of Src inhibitor (AZD-0530). Growth factors of TGF-β1, 
TGF- β3, EGF, FGF, HGF and PDGF were used to simulate section from 
HUVECs. Addition of growth factors could either slightly or fully restore T24 
dispersion. In the cases of FGF(FGF-2) and HGF are two to induce the highest 
dispersion among other growth factors. 
 
T24 aggregate dispersion was reduced to 40% of the original value in 
co-culture with HUVECs when treated with a neutralizing antibody against 
HGF (Figure 3-20c). The inhibition effect was the same as that achieved by 
individual drugs.  Interestingly, with T24 MCA alone, the antibody against HGF 
showed virtually no effect on dispersion, regardless of the presence or absence 
of AZD-0530. A neutralizing antibody against FGF-2 delivered similar 
inhibition to the one observed with anti-HGF antibodies. To validate the 
antibody inhibitory effects, c-Met inhibitor JNJ-38877605 (Johnson & Johnson) 
and FGFR inhibitor TKI-258 (Novartis) were applied each at 10µM. The results 
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were consistent with the antibody blocking experiment of anti-HGF and anti-
FGF-2, leading to dispersion values of approximately three. 
Some reports have previously indicated that HGF/c-Met pathway 
activation correlates with bladder cancer progression (Laidler, Gil et al. 2000; 
Wang, Nishitani et al. 2007; Sigurdsson, Hilmarsdottir et al. 2011). For example, 
fibroblast secreted HGF could influence invasive potential of bladder cancer 
cell (Wang, Nishitani et al. 2007). Our study showed that HUVECs could 
secrete HGF to promote dispersion of T24 cells by a mechanism independent 
of the Src pathway. ELISA and neutralizing antibody experiments further 
validated these findings (Figure 3-20). We also observed that FGF (FGF-2) 
played a similar role to HGF in promoting MCA dissociation, which could also 
be secreted by HUVECs (Figure 3-19). Previous literature has reported that 
FGF-2 could lead to EMT through Ras-MAPK pathway activation (De Medina, 
Popov et al. 1999; Antoine, Wirz et al. 2005), promoting T24 to become 





Figure 3-20. Analysis of endothelial cell secretion of HGF and FGF-2 in co-
culture or by T24 cells alone. (a) ELISA measurement of FGF-2 concentration. 
(b) ELISA measurement of HGF concentration. (c) Neutralized antibody 
blocking experiment (HGF and FGF-2).  
 
3.3.4 Summary of Part III 
This study described a modified microfluidic platform based on the previous 
design. Two cell lines with different invasiveness were identified. By 
combining CI-1033 and MK-2266 we found that we could reduce the 
concentration of each drug to one fifth of original concentration required for full 
inhibition in A549 MCAs. However, T24 MCA dispersion inhibition required 
higher doses of drugs as single agent and lead to only partial inhibition at 10 
µM concentration with a Src inhibitor AZD-0530. Near complete inhibition was 
obtained only when the 4 drugs were added in combination each at a 10µM 
concentration. The enhanced dispersal observed in the presence of HUVECs 
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accounts for the secretion of growth factors including HGF and FGF-2 by 
endothelial cells.  
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3.4 Part IV: Proof-of-concept multiplex system for high-
throughput screening4  
3.4.1 Multiplex co-culture microfluidic system  
In this last section, a proof-of-concept moderately high-throughout screening 
was demonstrated using multiplex co-culture microfluidic system (MCMS) 
(Figure 3-21). The design of MCMS consists of 15 media channels and 14 gel 
channels (see Kim et al., submitted, for more details). Each condition comprises 
three media channels and two gel channels, allowing two replicates for each 
condition. With this arrangement, up to 7 conditions were amenable for drug 
screening on one chip, which is in equivalent to downsizing 14 devices in one. 
To visualize microchannels and screening arrangement, 7 different 
concentrations of blue dyes were used. MCMS was fabricated by PDMS and 
boned on a non-treated cell culture dish. Semi-automated fluorescent imaging 
of each gel channel contained multiple MCAs was achieved by metamorph 
microscopy automation. Stitched images were taken at indicated time-points to 
monitor MCA dispersion.  
A proof of principle drug screen was performed to test the applicability 
of this procedure to semi-automated high-throughput drug screening assays 
using MCMS (Figure 3-22). AZD-0530 was added to the system at different 
concentrations. Effects on cell migration could be clearly observed by 
fluorescent imaging after 24 h. For semi-automated image analysis protocols, 
MCAs were labeled with CMFDA live cell staining. This step facilitates 
subsequent imaging analysis that was converted the original file to threshold. 
Results demonstrated significant dose-dependent response on drug treated 
MCAs. Quantitative image analysis based on the outline of MCA fitted well 
with drug responses, demonstrating the feasible concepts of both system design 
and analytical method. The MCMS can also be integrated into conventional 
fluorescent microscope systems with automatic acquisition stages to facilitate 
precise and rapid standardized imaging acquisition. 
                                                 





Figure 3-21. Schematic and device photo of a multiplex co-culture microfluidic 
system. The design consists of 15 media channels and 14 gel channels. Each 
condition comprises of three media channels comprised of two gel channels, 
allowing two replicates in one condition. With this arrangement, up to 7 
conditions could be screened on one chip, which is in equivalent to combining 
14 devices into one. Stitched fluorescent images showing two gel channels 
separated by a media channel. Each gel channel contained multiple MCAs at 
indicated time-points. Scale, 1 mm. 
  
Current Works	
C1 C2 C4 C5 C3 C6 C7 
C1 C2 C4 C5 C3 C6 C7 C1 C2 4  C3  7 
0h 
24h 
100 µM 50 µM 10 µM 1 µM 0.1 µM 0.01 µM 0.001 µM 




Figure 3-22. Screening on T24 MCA using automated imaging across 7 gel 
channels. (A) Upper, stitched images of gel channel with indicated 
concentration. T24 MCA were screen with AZD-0530, as previously proven 
effective to alleviate T24 MCA dispersion in the absence of HUVECs. MCA 
dispersion was analyzed by determining the outline of the MCA. (b) Dose-







3.4.2 Future work 
The investigative scope of using MCMS is amenable to medium-throughput 
screening via automation, which will allow the parallel study of multiple 
inhibitory compounds on cancer cell invasion, including varying levels of 
invasiveness of cancer cell lines. The MCMS can also be integrated into 
conventional fluorescent microscope systems with automatic acquisition stages 
to facilitate precise and rapid standardized imaging acquisition.  
 
  
Chapter 4 Conclusions and Future Directions 
This thesis proposed a novel drug screening platform that integrated 3D cancer 
model and endothelial cells for a biomimetic tumor microenvironment. In part 
I, a simple, economical, and high-throughput method for concave microwell 
prototyping on a conventional culture dish was introduced for reliably generate 
the MCAs for further device integration. Microwells generated by CO2 laser 
ablation on PMMA, PDMS, and PS materials were investigated and with each 
revealed distinctive structure. PS revealed the best surface smoothness and 
roundness among these three materials. The size of the generated microwells 
was found to be ~250 μm.  
A549 MCAs were successfully generated in the PS microwell in four 
days, and aggregate size could be controlled at ≈80 μm. MCA migration was 
examined in 2D and 3D conditions showing contrasting migration patterns due 
to the environmental dimensionality. The PS microwell dish presented is 
manufactured directly by patterning with a desktop CO2 laser, requiring no 
additional fabrication processes. Drilling a microwell requires less than 500 ms, 
and a pattern of 1,000 microwells can be generated in 2.5 min. Our approach of 
manufacturing a microwell array from a Petri dish facilitates liquid handling 
and ensures ease of material access suitable for most biological and medical 
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laboratories. This technique has potential applications in generating 3D 
multicellular aggregates for both basic and translational research in the future.  
In part II, preclinical therapeutic anti-cancer drug screening was 
performed to identify the effective dosage for 2D and 3D conditions. Results 
based on 3D screening correlated comparably with in vivo studies with IC50 
concentration fall ≈30 μM. MCAs were further used to integrate with 
microfluidic platform for validating in 3D drug screening assay. As a step 
toward a more realistic in vitro assay, we developed and demonstrated a 3D 
microfluidic system, and accompanying image analysis process to characterize 
the statistics of anti-metastatic drug responses. Results confirmed the 
importance of growing cells in 2D vs. 3D and that other cell types, in this case 
endothelial cells, can significantly alter the levels of drug required to inhibit 
MCA dissemination. These studies therefore offer a new approach in drug 
screening with the potential to better replicate the in vivo microenvironment. 
They also offer the prospect of including other cell types and matrices to 
produce even greater realism with tissue-specific characteristics in future 
studies. This platform provides a new basis for understanding the progression 
of carcinoma towards dedifferentiated and more malignant states. 
In part III, a modified microfluidic co-culture platform was proposed 
with improved HUVEC monolayer growth. The lung A549 and the bladder 
carcinoma T24 MCA were tested. Dose-response assays of four drugs were 
validated according their invasive capability to adjacent 3D matrix. In the 
absence of HUVECs, T24 MCAs showed dramatic spontaneous dissemination 
as compared to A549 MCAs. The presence of HUVECs in one channel induced 
MCA dispersion in A549 that then can be inhibited by each of the four drugs, 
which was in consistent with one-gel device. T24 MCA dispersion inhibition 
required higher doses of drugs as single agent and leaded to only partial 
inhibition at 10 µM concentration with a Src inhibitor AZD-0530. Near 
complete inhibition was obtained only when the 4 drugs were added in 
combination at a 10µM concentration. However, the efficacy of this near 
complete inhibition forfeited in the presence of HUVECs for T24 cells. The 
enhanced dispersal observed in the presence of HUVECs accounts for the 
secretion of growth factors including HGF and FGF-2 by endothelial cells. 
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Growth factor production is not affected by addition of AZD-0530 from one of 
the 4 drugs.  
Modifications to these systems could allow for high throughput 
screening of new compounds or combination therapies that maximize the 
inhibition of invasion while minimizing other adverse off target effects. Other 
cell types in addition to endothelial cells could also be added, either in the gel 
or the HUVEC-lined channel, to create a more realistic testing environment. 
Variations in the present design could also address other steps in the metastatic 
cascade such as intravasation. Since few methods exist today for screening 
drugs directed at reversing metastatic potential, systems such as this that mimic 
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Appendix I: Multicellular cancer aggregates generation  
1. Materials and methods 
Growth medium 
Phosphate buffered saline (PBS) 1X  
Coating solution: PBS 1X with dissolved 0.2% Pluronic F108, optional 
 
2. Specification of microwell plate  
 
Figure A1: Photograph of microwell plates made of conventional non-treated 
cell culture wares. 
 
The microwell plates are made of non-treated cell culture wares (Corning, Inc.), e 
current stocks of the microwell plates are used for three types of each are 100mm dish, 
60mm dish, and 12 well plate (Figure A1). 
The volume of reagent use, the number of microwells contained, and the number of 
cell seeding in each type of dish or plate are described (Table A1).  
Type MCA Pipette 
Volume (mL) 
MCA Pipette Volume by 1mL 
Tip (mL) 
 
100mm dish 8 2  
60mm dish 3 2  
12 well plate 1 1  
Table A1: The volume of reagent use, the number of microwells contained, and the 
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number of cell seeding in each type of dish. 
3. Preparation for microwell plate and cell seeding 
Prior to cell preparation 
1. Remove the parafilm wrapped to the microwell plate in a clean BSC. 
2. Aspirate the 70% ethanol at a corner of the dish.   
4. Add desired volume of washing buffer (referred to Table 1) to the prepared dish. 
5. Gently shake the dish for 3 seconds. 
6. Aspirate the washing buffer at a corner of the dish. 
7. Repeat step 4-6. 
(Optional, in grey)  
8.  Add desired volume of coating solution to the prepared dish.  
9. Wait for 1h to establish the uniform coating without UV exposure. 
10. Aspirate the coating solution at a corner of the dish.  
11. Add half of desired volume of growth medium to keep dish aqueous before 
adding cell suspension.     
Prior to cell seeding 
12.  Aspirate the growth medium at a corner of the dish 
13.  Seed cell suspension with desired amount of cells and medium volume (Table 
1). 
After cell seeding 
14. Gently leave the plate in the BSC for 10 min for cells to settle to the microwell. 
15.  The observation of cells in microwells can be done in conventional bright field 
microscope.  
16. Put the microwell plates in 37 °C incubator with 5% CO2. 
 
Type MCA Pipette 
Volume (mL) 
MCA Pipette Volume by 1mL 
Tip (mL) 
 
100mm dish 8 2  
60mm dish 3 2  




4. Retrieve multicellular cancer aggregates 
1. Use desired pipette to gently pipette dish surface with microwells 10 times. 
2. Transfer the MCA suspension to 15mL Falcon tube. 
3. Use another 1mL tip to gently pipette dish surface with microwells 10 times. 
4. Transfer the MCA suspension to the same 15mL Falcon tube.  
5. Filter the MCA suspension through a 100 μm strainer in a 50mL Falcon tube. 
6. Then filter the MCA suspension thorough 40 μm strainer in a 50mL Falcon tube. 
7. Flip the strainer, and add the growth medium to the other surface (bottom) of the 
strainer to a 50 mL Falcon tube. 
8. Re-suspend the MCA suspension to the desired concentration.
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Appendix II: Cells seeding in microfluidic device protocol 
1. Device diagram and description 
All devices contain a layer of gel held in place between two or more lines of 
micro-posts, which make a gel cage.  Surface tension keeps the gel between the 
posts, and specially shaped and treated micro-posts ensure the device is easy to 
fill and the gel-media interface remains flat and uniform.  This gel layer is thick 
enough for cells to migrate within three dimensions.  Meida channels next to 
the gel cages allow quick and accurate control over the cellular environment, 
using a minimum of cell culture media.  Cells may be cultured in any fluid 
channel or mixed into the gel before injection, or any combination thereof.   
 All devices were designed to suit different applications, and therefore 
different post geometries. The one-gel device is a generalized device with 
applications in investigating chemotaxis and cell migration, angiogenesis, and 
a variety of other cellular behaviors. The two-gel device is specialized for 
investigations involving applications where cells are mixed into the gel. The 
multiplex device lines up one-gel device design in parallel to scale up the 
throughput.   
 It should be noted that two-gel device is useful for setting up a co-culture 
where one cell type must be cultured alone for some time before a second cell 
culture is introduced into a gel suspension.  It can also be used for co-cultures 
where multiple cell types are suspended in collagen gel, and further cell types 
can be cultured in the media channel.  Media channels flanking both gel 
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channels allow for nutrient exchange and pressure and interstitial flow 
regulation.   
 
Figure B1: One-gel channel device. 
 




Figure B3: Multiplex channel device  
 
2. Device assembly 
 PDMS devices may come in a disassembled state.  The PDMS piece 
must be bonded to a glass microscope cover slip.  Most commercial cover slips 
will work for this application, and may be found next to most lab microscopes. 
Plasma treatment is used to bond the two pieces.  Glow discharge plasma 
chambers, such as the Femto Science COVANCE-2MP, create a volume of gas 
plasma between two electrodes at low gas pressures.  This renders the PDMS 
surface highly hydrophilic, and allows instant and permanent bonding to the 
glass cover slip that forms the floor of the device.   
To assemble the device: 
1. Immerse glass microscope cover slips in 100% ethanol for an hour, and bake 
in 70°C oven until dry 
2. Ensure all surfaces of the device are free from dust.  Dab with tape to remove 
dust if necessary 
3. Place glass covers slips and PDMS device in plasma chamber with the 
channels facing up 
4. Subject to glow discharge plasma for 40-180 seconds, depending on plasma 
chamber manufacturer.   
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5. Use a blunt tweezers to place the glass cover slips on the PDMS devices and 
press firmly to ensure no air bubbles remain between glass and PDMS 
3. Surface coating 
 Poly-D-Lysine (PDL) can be used to properly adhere cells to the fluid 
channel surface, and allow better attachment of the collagen gel to the device.  
This is best done within 8 hours of plasma treatment.  Devices may come pre-
coated, and a second coat will not harm the device. 
To coat the surface with PDL: 
1. Prepare 1 mL of 1 mg/mL PDL/PLL solution.  
2. Fill each device with at least 120 µL PDL solution, avoiding bubbles, by 
injecting the solution using a P200 pipette into one of the collagen filling ports 
(the smaller ports).  If a bubble forms, it must be removed to ensure proper 
device function 
3. Ensure that a small bubble of liquid is formed on the top of each filling port 
to prevent evaporation from building up high levels of PDL 
4. Leave in incubator for 4 hours 
5. Aspirate PDL solution 
6. Rinse device with tissue culture grade water (not PBS) 
7. Aspirate water and rinse again 
8. Aspirate water again and store in 70°C oven for 24-48 hours 
4. Gel filling  
To fill the one-gel and multiplex channels: 
1. Ensure that the devices are at room temperature or colder.  A warm device 
will cause premature polymerization of the collagen gel, and may lead to poor 
gel uniformity 
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2. Aspirate approximately 20 µL of collagen into a P20 pipette and fit pipette 
into one of the two gel filling ports, ensuring a tight fit 
3. Slowly dispense gel into the gel port, stopping when the gel has reached 
halfway up the gel channel 
4. Remove the pipette from the first gel filling port and place it firmly in the 
second gel filling port  
5. Slowly dispense gel into the second gel filling port, slowing down as the gel 
approaches the first region filled.  Stop when the two gel regions meet, and keep 
the pipette in the gel port for around 2 seconds to allow pressures to equalize.  
This ensures that the gel-media interface is flat throughout the device 
6. Remove pipette tips from the device. Place droplets of gel on both gel ports.  
This will keep evaporation from harming the gel in the gel cage 
7. Place in an incubator for 30 minutes to allow gel polymerization 
8. Fill media channels with cell-free media.. 
After step 8, the device in hydrated state is stable for up to 2 weeks, and cells 
can be seeded at any time. Advanced users may find it possible to fill the entire 
gel cage with collagen without having to fill from both ends. In this case, it is 
important to also fill in the second gel port with collagen to prevent evaporation 
from the gel ports.   
A gel-gel interface is formed when the gel injected from the second port meets 
gel injected from the first port.  This can be observed using second harmonic 
imaging, or in a confocal microscope using collagen’s auto-fluorescent spectra.   
To fill the two-gel channels: 
 Maintaining a proper gel-gel interface between the two adjacent gel 
channels is important, and requires some extra care.   
1. Ensure that the devices are at room temperature or colder.  A warm device 
will cause premature polymerization of the collagen gel, and may lead to poor 
gel uniformity 
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2. Cells or MCAs may be seeded into one or both gels.  
3. There is a small triangular feature on the device used to discern between 
channels, and traditionally the gel channel closest to the triangle is designated 
Channel B.  Channel A should be filled first, due to channel geometry.  Filing 
channel B first will often lead to a highly curved gel/gel interface, and has a far 
greater chance of gel spilling between channels during gel filling. 
4. Aspirate approximately 20 µL of collagen into a P20 pipette and fit pipette 
into one of the gel ports for Channel A 
4. Slowly dispense gel into the gel port, stopping when the gel has reached 
halfway up the gel cage 
5. Remove the pipette from the first gel filling port and place it firmly in the 
second gel filling port of Channel A 
6. Slowly dispense gel into the second gel filling port of Channel A, slowing 
down as the gel approaches the first region filled.  Stop when the two gel regions 
meet, and keep the pipette in the gel port for around 2 seconds to allow pressures 
to equalize.  This ensures that the gel-media interface is flat throughout the 
device 
7. Place devices in humidified containers in an incubator for 40 minutes to allow 
gel polymerization 
8. Fill Media Channel A with cell-free media. The device is stable, and can last 
up to a week before Gel Channel B must be filled.   
9. Aspirate approximately 8 µL of collagen into a P20 pipette and fit pipette into 
one of the gel ports for Channel B 
10. Slowly dispense gel into the gel port, stopping when the gel has filled 80% 
of the gel channels. 
12. Disconnect the pipette from the pipette tip 
13. Aspirate approximately 10 µL of collagen into a P20 pipette and fit pipette 
into the other gel port for Channel B. 
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14. Slowly dispense gel into the second gel filling port of Channel A, slowing 
down as the gel approaches the first region filled.   Carefully apply pressure to 
the pipette, dispensing all the 10 µL gel through the channel until the pipette tip 
is drained, forming a bubble of gel on the gel port on the other end.  This will 
remove any condensation that built up on the first gel region, forming a water 
barrier between the gel regions.   
17. Remove the pipette from the gel port, and apply a small bubble of gel to 
reduce evaporation 
18. Place devices in humidified containers in an incubator for 40 minutes to 
allow gel polymerization 
19. Flow cell-free media into Media Channel B.  
 
 
 
 
